Document:

License Agreement between the Registrant, LemnaGene S.A. & Yeda Reasearch

 Exhibit 10.6 
 LICENCE AGREEMENT 
 Made and entered into on this 7th day of July, 2005 
 (“the Effective Date”) 
 By
and Between: 
 YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED 

			
		  	  
 a company duly registered under the laws of Israel with an address at P 0
Box 95, Rehovot 76100, Israel
  

 (hereinafter, “Yeda”) 
 and 
 LEMNAGENE, S.A. 
  

			
		  	a company duly registered under the laws of France with an address at 46 Allée d’ Italie, 69364 Lyon, France

 (hereinafter, “the Company”) 
  

			
	WHEREAS:	  	in the course of research conducted at the Weizmann Institute of Science, Rehovot (“the Institute”), Professor Marvin (Meir) Edelman (“the Scientist”) of the Department of
Plant Sciences, together with certain other researchers (“the External Researchers”), has developed certain technology (“the Existing Technology”) relating to the production of heterologous proteins and peptides in transgenic
Lemnaceae plants, such technology constituting the subject matter of the patents and patent applications listed in Schedule A(1) hereto (“the Existing Patents” and “the Existing Patent Applications”, respectively) and has created
and/or generated the know-how and other information related to the Existing Technology as described in Schedule A(2) hereto (“the Know-How”); and
		
	WHEREAS:	  	pursuant to an agreement between the Institute of the first part, Yeda of the second part and the scientists employed by the Institute of the third part (including the Scientist)
collectively, (“the Institute Scientists”) and (with respect to the Existing Technology), pursuant to a further agreement between the External Researchers of the first part and Yeda of the second part, all right, title and interest
of the Institute Scientists, the External Researchers and the Institute in and to the Existing Technology, in and to the Patents (as hereinafter defined) and in and to the Know-How, vests and will vest in Yeda; and
		
	 WHEREAS:
	  	pursuant to that certain Agreement for Resolution of Patent Controversies of even date herewith between Yeda, the Company, North Carolina State University (“NCSU”), and
Biolex Incorporated (“Biolex”) (governing the settlement

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

			
		  	of a certain pending patent interference between Yeda and Biolex relating to the Patents) (“the Master Agreement”), it was agreed, inter alia, that Yeda shall, subject to the
terms and conditions of this Agreement, grant to the Company a licence under all of the Patents (to the extent still existing, following the Master Agreement); and
		
	WHEREAS:	  	the Company wishes to receive an exclusive worldwide licence, subject to and in accordance with the terms and conditions hereinafter set forth, for the use of the Existing Technology and the
Know-How and, under the Patents, for the development, manufacture and sale of products based on or comprising or incorporating Lemnaceae (regardless of the technology used for the creation and/or production of such products) and Yeda is willing to
grant the Company such a licence, all subject to the terms and conditions set out in this Agreement below,

 NOW, THEREFORE, IT IS HEREBY AGREED BY THE PARTIES AS FOLLOWS: 
  

	1.	STATUS OF RECITALS AND SCHEDULES; INTERPRETATION 

  

	1.1.	The recitals and Schedules hereto form integral parts of this Agreement. 

  

	1.2.	In this Agreement, the terms below shall bear the meanings assigned to them hereinafter. Any capitalized terms used herein that are not defined in this Agreement shall have the
meanings set forth in the Master Agreement, including Appendix 4 thereto: 

  

	1.2.1.	“Licence” shall mean the licence granted by Yeda to the Company pursuant to clause 4 below; 

  

	1.2.2.	“Master Agreement” shall bear the meaning ascribed to such term in the preamble hereto; 

  

	1.2.3.	“Patents” shall mean: (i) the Existing Patents; (ii) the Existing Patent Applications; (iii) all of Yeda’s patents and patent applications
claiming priority to the Edelman Application; (iv) all patents which may be granted on any of the foregoing patent applications; and (v) all continuations, continuations-in-part, patents of addition, divisions, renewals, reissues and
extensions of any of the foregoing patents; but excluding: (a) patents that have been invalidated or cancelled pursuant to the final (i.e., unappealed or unappealable) judgment of a competent court; and (b) patent applications that have
been withdrawn or have expired, in each case such exclusion to be effective only from the date of such invalidation, cancellation, withdrawal or expiry, as the case may be. For the purposes of this Agreement, the term “Patent” shall also
mean “Orphan Drug” status 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	    	(within the meaning of such term under the US Orphan Drug Act), Supplementary Protection Certificate (within the meaning of such term under Council Regulation (EU) No. 1768/92
or any other similar statutory protection); 

  

	1.2.4.	“Prior Agreement” shall have the meaning ascribed to such term in clause 15.4.1 below; 

  

	1.2.5.	“Product” shall have the meaning set forth in Appendix 4 of the Master Agreement. 

  

	2.	TITLE 

  

	2.1.	It is hereby agreed that all right, title and interest in and to the Existing Technology, the Patents and the Know-How (collectively, “the Yeda Information”) and in
and to any and all drawings, plans, diagrams, specifications, documents and other media in any way embodying or containing the Yeda Information (or any part thereof) vests and shall vest in Yeda exclusively, subject to the Licence granted to the
Company under the terms of this Agreement. 

  

	2.2.	For the avoidance of doubt, it is agreed that nothing in this Agreement shall constitute a representation or warranty by Yeda that the Yeda Information or any part thereof will be
commercially exploitable or of any other value and Yeda furthermore makes no warranties and representations whatsoever as to the Yeda Information. 

  

	2.3.	The Company hereby acknowledges that: 

  

	2.3.1.	the Company is aware that certain research conducted at the Institute under the supervision of the Scientist, which relates to the Existing Technology and the Patents, [*****]; and

  

	2.3.2.	the Company is further aware that [*****]. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	2.4.	Yeda shall be entitled, after consulting with the Company, but at Yeda’s sole discretion, to approach the Government with a view to resolving any outstanding ownership or other
claims that the Government may have as a result of the Government Grant in connection with the Patents. In addition, during the term of this Agreement, the Company may request that Yeda approach the Government with a view to a resolution of any
outstanding ownership or other claims that the Government may have with respect to the Patents in connection with the Government Grant. In the event that Yeda desires to initiate such a discussion with the Government (whether or not at the
Company’s request), Yeda and the Company will discuss and, within thirty (30) days, will seek to develop a mutually agreeable plan for Yeda to approach the Government. In the event that the parties have agreed on a plan, Yeda will use
commercially reasonable efforts to implement such plan. It is expressly agreed, for the avoidance of doubt, that failure to agree on a plan shall not derogate from Yeda’s right to approach the Government as provided in the first sentence of
this clause 2.4. Yeda will provide the Company with copies (or copies of the relevant parts) of all official correspondence received from the Government regarding the foregoing matters. Without limiting Yeda’s discretion, Yeda will take into
account any suggestions that the Company may deliver to Yeda in connection with any negotiations or correspondence between the Government and Yeda as aforesaid. Notwithstanding anything to the contrary in this clause 2.4; only Yeda will be in
contact with the Government with respect to any Government claims to the Patents and Yeda shall be entitled, in its sole discretion, to reach any arrangement or settlement with the Government (without derogating from clause 2.4.2 below which will be
applicable in the case of a claim by the Government against the Company or Biolex). 

  

	2.4.1	In the event that the Government is awarded, by final judgment or settlement (which settlement is approved by Yeda), ownership of any or all of the Patents and the Government does
not, despite Yeda using all commercially reasonable efforts to cause the Government to do so, either: (i) authorise Yeda to continue the Licence under the terms of this Agreement, or (ii) consent to being a joint licensor with Yeda subject
to the terms of this Agreement, then: 

  

	 	(a)	If the operation of the Licence is prevented entirely, then Biolex shall be entitled to cease all payments to Yeda pursuant to Appendix 4 of the Master Agreement in respect of the
period after such judgment or settlement as aforesaid and the Company shall be entitled to terminate this Agreement. Yeda will reimburse Biolex and the Company for any reasonable out of pocket expenses incurred by the Company or Biolex in connection
with such judgment or settlement. 

  

	 	(b)	 In any event, if Biolex’s payments are not terminated pursuant to the foregoing clause 2.4.1(a), then Biolex shall be entitled to an appropriate reduction in
future payments under Appendix 4 of the Master Agreement to take into account the reduction in the value of the Licence, as such reduction shall be agreed between Yeda and Biolex. In the event of 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	 	 
any dispute between Yeda and Biolex as to the amount of such reduction that is not resolved by the Parties after thirty (30) days of discussion, either
Party may request the International Chamber of Commerce (“the ICC”) to appoint an expert, in accordance with the Rules for Expertise of the ICC, to finally resolve the dispute. The expert will render a decision in writing within 30
(thirty) days of the submission of the dispute for resolution; provided, that the expert will have discretion to extend the time frame for reaching the Expert’s decision regarding the dispute at issue. The Expert will be entitled to request
information from the Parties, hold a hearing or hearings and take all other actions as the Expert shall deem necessary or appropriate, in the Expert’s discretion, for reaching the Expert’s decision regarding the dispute at issue. The
decision of the Expert shall be final and binding on the Parties. In determining such reduction, the parties and the expert shall take into account the Patents to which the Government’s rights apply and the nature of the Government’s
retained ownership and other rights with respect to such Patents, as well as the overall transaction between Yeda and Biolex pursuant to the Master Agreement. 

  

	2.4.2.	In the event that, on the basis only of the Government Grant or arising out of or relating thereto, the Government shall claim a right to payment from the Company or Biolex or any
of its sublicensees, any damages, fees or other amounts (collectively, “Compensation”), then the Company shall promptly give notice of such claim to Yeda and the procedure pursuant to clause 9.5 below shall apply, mutatis mutandis,
to such claim (for such purpose, as if Yeda were the Indemnifying Party and the Company, Biolex or its sublicensees, as applicable, were the Indemnified Parties). In the event that following such claim and compliance with the procedure under clause
9.5 below, any Indemnified Party shall be required, under a final judgment or settlement; which settlement is approved by Yeda (not to be unreasonably withheld,), to pay to the Government any Compensation, then Biolex shall be entitled to deduct
from payments due by it to Yeda pursuant to Appendix 4 of the Master Agreement in respect of the period after such judgment or settlement as aforesaid, any such Compensation actually paid by Biolex to the Government and any reasonable out of pocket
expenses incurred by the Company or Biolex in connection with such judgment or settlement. 

 The Company hereby agrees and acknowledges that
the remedies set out in this clause 2.4 above shall be sole and exclusive remedies available to the Company, Biolex, their respective Affiliates, Sublicensees, and their respective directors, officers, employees and agents arising out of or relating
to the Government Grant or any consequences thereof. 
  

	3.	PATENTS 

  

	3.1.	During the term of the Licence, Yeda shall (a) prepare, file and prosecute those of the Yeda Patent Applications which Yeda and Biolex agreed, pursuant to the Settlement
Agreement, shall be prosecuted, and (b) maintain and renew the Yeda Patents. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	3.2.	All such Yeda Patent Applications filed by Yeda in accordance with the terms of clause 3.1 above, shall be in the name of Yeda or, if the law of the relevant jurisdiction so
requires, in the names of the inventors and then assigned to Yeda. 

  

	3.3.	Yeda shall be responsible for maintaining at the applicable patent office the Yeda Patents and any patents issuing from the Yeda Patent Applications to be prosecuted pursuant to
clause 3.1 above (as well as the Existing Patents), unless otherwise agreed pursuant to this Agreement or the Master Agreement. 

  

	3.4.	In preparing, filing and prosecuting patent applications and in maintaining Patents in accordance with clauses 3.1 and 3.3 above, Yeda shall retain outside patent counsel selected
by the Company, subject to Yeda’s approval of the identity of such patent counsel, not to be unreasonably withheld; provided that, until such time as the US Board of Patent Appeals and Interferences approves the Settlement Agreement, Yeda shall
retain the right to select and use patent counsel of its choice. Yeda will provide the Company with copies of all official correspondence received from patent offices relating to the Yeda Patent Applications and Yeda Patents, and with any proposed
substantive responses thereto sufficiently in advance for the Company to provide comments and suggestions on such proposed responses. Yeda will give reasonable consideration to any comments or suggestions provided by the Company.

  

	3.5.	The Company shall bear and pay any and all costs, fees and expenses in connection with: (i) the preparation, filing, and prosecution and maintenance of all Yeda Patent
Applications and of all patents issuing from any such patent applications; and (ii) the maintenance and renewal of all Yeda Patents. Unless otherwise instructed by Yeda in writing, the Company shall pay directly to Yeda’s relevant outside
patent counsel all amounts payable by the Company pursuant to this clause 3.5 above. 

  

	    	Without derogating from the generality of the foregoing, the Company shall, within 30 (thirty) days of Yeda giving to the Company a written report to such effect (supported by
appropriate documentation evidencing such costs, fees and expenses) pay directly all amounts incurred in respect of the Existing Patent Applications and Existing Patents during the period prior to the date of signature of this Agreement, including,
without limitation, in connection with all interference proceedings relating to such patent applications or patents. 

  

	3.6.	 Should the Company determine that a third party is infringing one or more of the Patents, then the Company shall, after first having consulted Yeda, be entitled to
sue for such infringement Yeda may elect, at its own initiative and expense, to join as a party to any such action. Yeda will, at the Company’s request, consent to being named as a party to such action, provided that the Company shall have
provided Yeda with security, reasonably satisfactory to Yeda, for the payment of all expenses and costs referred to in paragraph (1) below, and Yeda shall cooperate and shall use its reasonable efforts to cause the 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	 	 
Scientist to cooperate with the Company in prosecuting or defending such litigation, provided that: (1) any expenses or costs or other liabilities
incurred in connection with such litigation (including attorneys’ fees, costs and other sums awarded to the counterparty in such action) shall be borne by the Company, who shall indemnify Yeda against any such expenses or costs or other
liabilities, the above without derogating from the provisions of clause 9 below; (2) in the event that Yeda shall be named as a party in any such litigation then Yeda shall be entitled to select its own legal counsel in such litigation, at the
Company’s expense, and if Yeda elects not to do so and the Company has requested Yeda to be named in such litigation, the selection of the legal counsel representing the Company and Yeda in such litigation shall be subject to the prior written
approval of Yeda, which approval shall not be withheld unreasonably; (3) no settlement, consent order, consent judgment or other voluntary final disposition of such action that undermines the validity or enforceability of the Patents may be
entered into without the prior written consent of Yeda. Any recovery in any litigation commenced under this clause 3.6 shall, to the extent attributable to infringement of the Patents by the third party, be applied as follows: (a) first, to
cover the parties’ costs incurred in connection with the litigation, (b) second, the Company will retain any recovery attributable to lost sales of the Company or its affiliates, in respect of which Biolex pays royalties on Net Sales
payable in accordance with Appendix 4 of the Master Agreement, and (c) thereafter, divided [***]% ([***] percent) to the Company and [***]% ([***] percent) to Yeda. 

  

	3.7.	Should the Company be sued on the grounds that the manufacture, use or sale of a Product by it or by a Sublicensee under any of the Patents or using the Yeda Information or any
portion thereof infringes upon the patent rights of a third party, then the Company shall, after first having consulted Yeda, be entitled to defend such action; provided, that the Company will be entitled to indemnity from Yeda with respect only to
any such claim relating to the matters described in clause 9.4 below. In any event, Yeda shall cooperate and shall use its reasonable efforts to cause the Scientist to cooperate with the Company in defending such litigation, provided that:
(1) any expenses or costs or other liabilities incurred in connection with such litigation (including attorneys’ fees, costs and other sums awarded to the counterparty in such action) shall be borne by the Company, who shall indemnify Yeda
against any such expenses or costs or other liabilities, the above without derogating from the provisions of clause 9 below; (2) in the event that Yeda shall be named as a party in any such litigation then Yeda shall be entitled to select its
own legal counsel in such litigation, at the Company’s expense; (3) no settlement, consent order, consent judgment or other voluntary final disposition of such action that undermines the validity or enforceability of the Patents may be
entered into without the prior written consent of Yeda, which consent shall not be withheld unreasonably. 

  

	3.8.	 If the Company fails to take action to abate any alleged infringement of a Patent as referred to in clause 3.6 above or to defend any action as referred to in
clause 3.7 above within 60 (sixty) days of a request by Yeda to do so (or within a shorter 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	 	 
period, if required to preserve the legal rights of Yeda under applicable law), then Yeda shall have the right (but not the obligation) to take such action
at its expense and the Company shall cooperate in such action at the Company’s expense and, if required under applicable law or contract, consent to be named as a party to any such action. Yeda shall have full control of such action and shall
have full authority to settle such action on such terms as Yeda shall determine. Any recovery in any such litigation shall be for the account of Yeda only. 

  

	3.9.	If the Company initiates any action pursuant to clause 3.6 above or becomes aware of any action initiated by any third party concerning any alleged infringement, or discovers any
allegation by a third party of infringement resulting from the Patents, then the Company shall so notify Yeda promptly in writing, giving full particulars thereof. If Yeda becomes aware of any action initiated by any third party concerning any
alleged infringement, or discovers any allegation by a third party of infringement resulting from the Patents, then Yeda shall so notify the Company promptly in writing, giving full particulars thereof. The Company shall promptly keep Yeda informed
and provide copies to Yeda of all documents regarding all actions or proceedings instituted by or against the Company as contemplated under any of the provisions of clauses 3.6 and 3.7 above. 

  

	3.10.	Nothing herein contained shall be deemed a warranty by Yeda that the Existing Patent Applications will be granted, or that the Existing Patents or any patents obtained on any of the
Existing Patent Applications, if obtained, will be valid or will afford any protection, or that the use of the Yeda Information will not infringe the rights of any third party. 

  

	3.11.	For the purposes of this clause 3, “Yeda Patent Applications” shall mean any patent applications included in the definition of Patents, including, without
limitation, the Existing Patent Applications and “Yeda Patents” shall mean any patents included in the definition of Patents, including, without limitation, the Existing Patents. 

  

	4.	LICENCE 

  

	4.1.	Yeda hereby grants to the Company and the Company hereby accepts from Yeda, an exclusive worldwide licence (“the Licence”), with the right to grant and authorize
the grant of further sublicences as described in and subject to clauses 4.3 and 4.4 below, under Yeda’s right, title and interest in and to the Yeda Information (including, without limitation, the Patents) to research, develop, make, have made,
use, sell, offer for sale, import, and otherwise exploit Products. 

  

	4.2.	[Section intentionally left blank.] 

  

	4.3.	 A Sublicence (as hereinafter defined) under the Licence may be granted by the Company or its Sublicensees only if such Sublicence meets the conditions set out in
this clause 4.3 below, or, if to an Affiliate (as such term is defined in Section 1.1 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	 	 
of Appendix 4 to the Master Agreement) of the Company (“a Company Affiliate”), only if such Sublicence to a Company Affiliate meets the
conditions set out in clause 4.4 below. 

  

	    	Without derogating from clause 4.4 below, such Sublicence to a third party (such party receiving a Sublicense, a “Sublicensee”) shall be permitted without the
consent of Yeda if such Sublicense is made in a bona fide arm’s length transaction between the Company and the third party (“a First Tier Sublicensee”) or between the Company’s Sublicensee and a third party (“a
Second-Tier Sublicensee”) where the principal consideration for the Sublicense is either monetary or the value of which is readily determinable, is made by written agreement, the provisions of which are consistent with the terms of this
Agreement and, further provided that: 

  

	4.3.1.	the Sublicence shall expire automatically on the termination of this Agreement for any reason, other than expiration pursuant to clause 10.1 below; 

  

	4.3.2.	the Sublicence shall include all terms necessary to enable performance by the Company of its obligations hereunder, including, without limitation, its obligations under this clause
4.3 and the performance by Biolex and/or the Company of its respective obligations under the Master Agreement, including Appendix 4 thereto; without derogating from the generality of the aforegoing, the Sublicense shall include provisions
corresponding to the first sentence of Section 3.1.3 and to Section 3.3 of Appendix 4 of the Master Agreement (“Appendix 4”). The Company agrees, at Yeda’s request, to exercise its rights pursuant to such provisions
(including the right to require compliance by First Tier Sublicensees thereto) and to procure the exercise of such rights pursuant to such provisions by a First Tier Sublicensee (including the right to require compliance by Second-Tier Sublicensees
thereto) and to advise Yeda on the outcome of such exercise of rights to the extent necessary for Yeda to ascertain fulfillment of its rights under this Agreement and/or the Master Agreement, including Appendix 4 thereto, provided that (i) Yeda
may request the exercise of inspection rights, pursuant to provisions corresponding to Section 3.3.1 of Appendix 4, by the Company or by any First-Tier Sublicensee, no more than once in any calendar year; (ii) if Yeda shall so request, the
person designated to carry out any such inspection shall be a person selected by Yeda, having no previous relationship with Yeda, (iii) Yeda will bear any fees and expenses in connection with the conduct of such a requested inspection, unless
such inspection (whether of a First-Tier Licensee or of a Second-Tier Licensee) reveals any underpayment(s) by such Sublicensee of more than five percent (5%), in which case, as between Biolex and Yeda, Biolex shall bear the fees and expenses in
connection with the conduct of such audit, and (iv) in provisions in a Sublicense . corresponding to Section 3.1.3 of Appendix 4, the reference to a written report signed by the Company’s Chief Financial Officer may be replaced by a
reference to a senior financial official of the First Tier Sublicensee or Second Tier Sublicensee, as the case may be. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	4.3.3.	any act or omission by the Sublicensee which would have constituted a material breach of this Agreement by the Company had it been the act or omission of the Company or a material
breach of Sections 3.1.3 or 3.3 of Appendix 4 by Biolex or the Company, had it been the act or omission of Biolex or the Company or any material breach of the payment obligations of the Sublicensee under the Sublicense agreement, shall constitute a
material breach of the Sublicense agreement with the Company entitling the Company to terminate the Sublicence (where the breach is by a First-Tier Sublicensee) or to procure the termination of the Sublicense by the First-Tier Licensee (where the
breach is by a Second-Tier Sublicensee) and the Company hereby undertakes to inform Yeda forthwith upon receipt of knowledge by the Company of such breach (and to cause each First-Tier Sublicensee to inform the Company forthwith upon receipt of
knowledge by it of such breach by a Second-Tier Sublicensee) and, at the written request of Yeda, to exercise such right of termination or right to procure termination, as the case may be (subject, in any event, to the Sublicensee’s right to
cure such breach); and 

  

	4.3.4.	a copy of the agreement granting the Subticence shall be given to Yeda promptly upon its execution. 

  

	4.3.5.	Except that a Sublicence granted to a First-Tier Licensee may be sublicensed to a Second-Tier Sublicensee, subject and in accordance with the terms hereinbefore specified in that
regard, a Sublicense shall not be assignable, further sub-licenseable or otherwise transferable, in whole or in part. 

  

	    	For the purposes of this Agreement, “Sublicence” shall mean any right granted, licence or consent given, or agreement entered into, by the Company, its Affiliates
or its Sublicensees, to or with any other person or entity, granting such person or entity a sublicense under the Licence (or an option or other right to obtain such a sublicence). 

  

	4.4.	Sublicences under the Licence may be granted by the Company to a Company Affiliate, provided that: 

  

	4.4.1.	the Sublicence agreement shall be in writing, shall be consistent with the terms of the Licence, and shall comply with the terms and conditions set out in clauses 4.3.1, 4.3.2,
4.3.3 and 4.3.4 above; provided (i) that if the Sublicense is to Biolex, Biolex may grant a Sublicense in accordance with and subject to clause 4.3 above (including the opening paragraph thereof) and Biolex’s Sublicensee shall have the
right to grant one further Sublicense in accordance with and subject to clause 4.3 above (including the opening paragraph thereof), (ii) that if .the Sublicense is to another Affiliate of the Company, such Affiliate may grant a Sublicense in
accordance with and subject to clause 4.3 above (including the opening paragraph thereof), but such other Affiliate Sublicensee shall not have the right to grant further Sublicenses and (iii) except as provided in paragraphs (i) and
(ii) above, no Sublicense to any Affiliate shall be assignable, further sub-licenseable or otherwise transferable, in whole or in part; and 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	4.4.2.	any act or omission by a Company Affiliate which would have constituted a breach of this Agreement by the Company had it been the act or omission of the Company or which would have
been a breach of Appendix 4 of the Master Agreement by Biolex or the Company had it been the act or omission of Biolex or the Company, shall be deemed a breach of this Agreement; and 

  

	4.4.3.	the Company Affiliate shall remain a Company Affiliate and is and shall remain an Affiliate of Biolex or of a permitted assignee of all of Biolex’s rights and obligations under
the Master Agreement pursuant to Section 9.5 thereof. 

  

	5.	PAYMENTS 

  

	    	It is recorded that, as part of the consideration for Yeda’s consent to the Master Agreement and for the Licence granted hereunder, Biolex (which holds the entire issued share
capital of the Company), will make certain payments to Yeda pursuant to the Master Agreement, as described in further detail therein. 

  

	6.	DEVELOPMENT AND COMMERCIALIZATION 

  

	6.1.	The Company shall use all reasonable commercial efforts during the period of the Licence to develop and diligently to commercialize Products throughout the world. Any efforts of
Biolex, any other Affiliates of the Company, or any Sublicensees will be deemed efforts of the Company for purposes of determining the Company’s compliance with its obligations under this clause 6.1. 

  

	6.2.	The Company shall provide Yeda with annual reports on the progress and results of the development and commercialization of Products by Company and its Sublicensees. If the Company
creates development and/or marketing plans for any Products, such plans will be included in the annual reports to Yeda. 

  

	6.3.	For the removal of doubt, nothing contained in this Agreement shall be construed as a warranty by the Company that any development activities to be carried out by the Company or its
Sublicensees will be successful, and the Company makes no warranties whatsoever as to any results to be achieved in consequence of the carrying out of such development work. 

  

	7.	CONFIDENTIALITY 

  

	7.1.	 “Confidential Information” shall mean, with respect to a party, all information disclosed by such party to the other party in connection with the
Prior Agreement or this Agreement at any time (including without limitation prior to the Effective Date), whether disclosed in oral, written, graphic or electronic form, and that is marked Confidential or that would be considered by a reasonable
person to be the confidential and proprietary information of such disclosing party. Subject to the provisions of this clause 7, each party receiving Confidential Information of the other party shall maintain in full confidence such 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	 	 
Confidential Information and shall use such Confidential Information only as permitted under this Agreement. Each party will only permit access to
Confidential Information of the other party to those of its directors, officers, employees, agents, Affiliates, Sublicensees or authorized representatives having a need to know such Confidential Information and who have signed confidentiality
agreements or are otherwise bound by confidentiality obligations at least as restrictive as those contained in this Agreement. 

  

	    	The foregoing obligations of confidentiality and non-use shall not apply to any Confidential Information to the extent that such information: (i) is in the public domain at the
date of this Agreement or becomes part of the public domain thereafter (other than through a violation by the receiving party of its obligation of confidentiality); (ii) was in the receiving party’s possession free of any obligation of
confidence at the time it was disclosed to receiving party; or (iii) was rightfully communicated to the receiving party free of any obligation of confidence subsequent to the time it was disclosed to the receiving party.

  

	    	Notwithstanding the terms set forth in this clause 7.1, a receiving party may disclose Confidential Information of the disclosing party to the extent that such disclosure is:

  

	 	(a)	made in response to a valid order of a court of competent jurisdiction or other governmental or regulatory body of competent jurisdiction; provided, however, that the receiving
party will first have given notice to the disclosing party and given the disclosing party a reasonable opportunity to quash such order and to obtain a protective order requiring that the Confidential Information and documents that are the subject of
such order be held in confidence by such court or governmental or regulatory body or, if disclosed, be used only for the purposes for which the order was issued; and provided, further, that if a disclosure order is not quashed or a protective order
is not obtained, the Confidential Information disclosed in response to such court or governmental order will be limited to information that is legally required to be disclosed in response to such court or governmental order;

  

	 	(b)	otherwise required by law or by the rules of a nationally-recognized securities exchange; provided, however, that the disclosing party will provide the receiving party with notice
of such disclosure in advance thereof to the extent practicable; 

  

	 	(c)	made by the receiving party to the regulatory authorities as required in connection with any application, filing, or similar requests for regulatory approvals; provided, however,
that reasonable measures will be taken to ensure confidential treatment of such information; or 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	 	(d)	made by the receiving party to existing or potential acquirers or merger candidates, potential collaborators (to the extent contemplated in this Agreement), investment bankers,
existing or potential investors, venture capital firms or other financial institutions or investors for purposes of obtaining financing, each of whom prior to disclosure must be bound by obligations of confidentiality and non-use at least as
protective of the disclosing party’s Confidential Information as those set forth in this clause 7. 

  

	7.2.	Without derogating from the aforegoing, each party undertakes not to make a public disclosure that mentions the names of the other party, Company Affiliates, the Institute or any of
the Institute Scientists in any manner or for any purpose whatsoever in relation to this Agreement, its subject-matter and any matter arising from this Agreement, unless the prior written approval of the other party to such mention and to the
wording thereof has been obtained. 

  

	7.3.	Clause 7.1 or 7.2 above shall not prevent the Company from mentioning the names of Yeda and/or the Institute or from disclosing any information where and to the extent that such
mention or disclosure is to competent authorities for the purposes of obtaining approval or permission for the exercise of the Licence or is in the fulfilment of any legal duty owed to any competent authority (including, without limitation, a duty
to make regulatory filings); provided that, any mention in a private placement memorandum or a public offering statement shall not be deemed fulfilment of a legal duty to a competent authority and any such mention shall be subject to Yeda’s
consent, which consent shall not be unreasonably withheld. 

  

	7.4.	Subject to clause 7.5 below, Yeda shall, during the period of the Licence, maintain in confidence the Yeda Information, except to the extent: (i) that any such Yeda Information
is in the public domain at the date of signature hereof or becomes part of the public domain thereafter other than through a violation by Yeda of this obligation of confidentiality; (ii) that Yeda is required to disclose such information in
order to fulfil its obligations under this Agreement (including, without limitation, in connection with the filing and prosecution of patent applications or in order to fulfil its obligations under the terms of the Government Grant or for dealing
with the claims raised by Porath as referred to in clause 2.3.2 above); (iii) as reasonably required to be disclosed by Yeda in connection with approaching, or negotiating with. a third party with a view to granting such third party a licence
in respect of the Yeda Information other than in relation to the Products, or in connection with the granting of such a licence; provided that, such third party is bound by a confidentiality obligation similar to that imposed on Yeda pursuant to
this clause 7; or (iv) Yeda is required to disclose such information in fulfilment of any legal duty owed to any competent authority. 

  

	7.5.	 Notwithstanding the provisions of clause 7.4 above, Yeda has the right to allow the Scientist to publish articles relating to the Yeda Information in scientific
publications or posters or to give lectures or seminars to third parties relating to the Yeda Information; provided that, to the extent that the information to be disclosed is not in the public domain, publication 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	 	 
thereof as aforesaid shall not take place unless the text thereof has been submitted to the Company at least 30 (thirty) days prior to the intended date of
submission of the article for publication, so as to give the Company a reasonable opportunity to check patentability of the information and to request the filing of a patent application relating to the subject-matter of the article pursuant to
clause 3. 

  

	7.6.	Termination of this Agreement, for whatever reason, shall not release either party from any of its obligations under this clause 7 and such obligations shall survive termination as
aforesaid; provided, that Yeda’s obligation of confidentiality pursuant to clause 7.4 shall lapse upon termination of this Agreement. 

  

	8.	ASSIGNMENT 

  

	    	The Company may not assign all or any rights or obligations under this Agreement or arising therefrom, without the express prior written consent of Yeda (not to be unreasonably
withheld, conditioned or delayed); provided that Company may freely assign all of its rights or obligations under this Agreement and such consent of Yeda shall not be required with respect to any assignment (whether by contract, operation of law or
otherwise) made (i) to Biolex, (ii) in connection with a an assignment of the Master Agreement, to the extent permitted under the Master Agreement, (iii) to a successor-in-interest to or purchaser of the whole, or the major part, of
the Biolex Lemnaceae Business, or (iv) in connection with any Biolex Sale Event. Any assignee permitted in accordance with the aforegoing shall assume in writing all the Company’s obligations under this Agreement. 

 

	9.	INDEMNIFICATION 

  

	9.1.	Yeda, the Institute and the respective directors, officers and employees of Yeda and/or of the Institute (collectively, “the Indemnitees”) shall not be liable and the
Company shall bear and undertake full responsibility and liability for any and all claims, demands, liabilities, costs, losses, damages or expenses (including legal costs and attorneys’ fees) of whatever kind or nature caused to or suffered by
any person or entity (including to the Company or any Sublicensee) that directly or indirectly arise out of, or result from, or are incidental to, the Prior Agreement, this Agreement, or the exercise of the Licence, including, without limitation,
directly or indirectly arising out of, or resulting from, or incidental to: (i) the development, manufacture, sale or use of any of the Products by the Company, any Sublicensee or any person acting in the name of or on behalf of any of the
foregoing, or acquiring any of the Products from any of the foregoing; or (ii) the exploitation or use by the Company or any Sublicensee of the Yeda Information or any part thereof, including, without limitation, of any data or information
given, if given, in accordance with the Prior Agreement or this Agreement; but excluding, in any event, damages from claims in respect of which the Company is entitled to the remedies as referred to in clause 2.4 above or to an indemnity as referred
to in clause 9.4 below. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	9.2.	In the event that any of the Yeda Indemnitees suffer any damages, claim, demand, liability, loss, cost or expense as aforesaid in clause 9.1, or shall be requested or obliged to pay
to any person or entity any amount whatsoever as compensation for any damages, demand, claim, liability, cost, loss or expense as aforesaid, then the Company shall indemnify and hold harmless such Yeda Indemnitees from and against any and all such
damages, claim, demand, liability, cost, loss or expense (including attorneys’ fees and legal costs) of whatever kind or nature as aforesaid. Without limiting the generality of the aforegoing, the Company’s indemnification as aforesaid and
the exclusion of liability in clause 9.1 above shall extend to product liability claims and to damages, claims, demands, liabilities, losses, costs and expenses attributable to death, personal injury or property damage or to penalties imposed on
account of the violation of any law, regulations or governmental requirement. 

  

	9.3.	The Company or its Affiliates shall throughout the term of this Agreement and for 7 (seven) years thereafter at its own expense maintain general liability insurance, products
liability insurance, or clinical trial insurance, as applicable, to insure its liability pursuant to clause 9.2 above in connection with the Company’s development, manufacture, sale or use of Products. Such insurance shall be in reasonable
amounts and on reasonable terms in the circumstances, having regard, in particular, to the nature of the Products. The beneficiaries of such insurance shall include Yeda and the Institute. The policy or policies so issued shall include a
“cross-liability” provision, pursuant to which the insurance is deemed to be separate insurance for each insured and beneficiary (without right of subrogation as against any of the insured or beneficiaries under the policy, or any of their
representatives, employees, officers, directors or anyone in their name) and shall further provide that the insurer will be obliged to notify each insured and beneficiary in writing at least 30 (thirty) days in advance of the expiry or cancellation
of the policy or policies. The Company hereby undertakes to comply punctually with all obligations imposed upon it under such policy or policies and, in particular, without limiting the generality of the aforegoing, to pay in full and punctually all
premiums and other payments for which it is liable pursuant to such policy or policies. The Company shall be obliged to submit to Yeda, at Yeda’s request, copies of the aforesaid insurance policy or policies. 

  

	9.4.	 Yeda will indemnify the Company, Biolex, their respective Affiliates, Sublicensees, and their respective directors, officers, employees and agents (collectively,
“the Company Indemnitees”), and defend and hold each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) caused to or suffered by
the Company Indemnitees resulting from a claim on the grounds that Yeda has infringed Porath’s plant breeder’s rights (if any) in respect of the species Galilee Plant (Hirfash, CV Galilee, Lemma Gibbash) (but not for claims relating to the
use by any of the Company Indemnitees of the species of the Galilee Plant (Hirfash, CV Galilee, Lemma 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	 	 
Gibbash). The Company hereby agrees and acknowledges that the indemnity set out in this clause 9.4 above shall be the sole and exclusive remedy available to
the Company Indemnitees arising out of or in connection with any of the matters referred to in clause 2.3.2 above or the consequences thereof. 

  

	9.5.	In the event that a party shall receive notice of any claim (“a Claim”) to which such party (“the Indemnified Party”) is entitled to indemnity from the other
party (“the Indemnifying Party”) under clause 2.4, 9.1, 9.2, or 9.4, as applicable, the Indemnified Party shall promptly give notice of such Claim to the Indemnifying Party. Notice shall be given in any event not less than 5 (five)
Business Days after the Indemnified Party has received written notice of such Claim. Failure to give such notice, however, shall not affect the Indemnified Party’s right to indemnification unless and to the extent the Indemnifying Party is
prejudiced by such failure. The Indemnifying Party shall have the right, at its expense, to be represented by counsel of its choice and to control the defence of any Claim for which indemnification is given pursuant to this clause 9. By doing so,
the Indemnifying Party shall not be deemed to waive any right to challenge the claim for indemnity hereunder. If the Indemnifying Party takes control of the Claim, the Indemnified Party may participate in the defence of any such Claim with counsel
of its choice and at its expense, to the extent that such participation does not interfere substantially with the Indemnifying Party’s control of such defence. To the extent that the Indemnifying Party elects not to defend any such Claim, the
Indemnified Party shall act reasonably and shall not enter into any settlement without the Indemnifying Party’s consent, which consent shall not be unreasonably withheld. The parties shall cooperate fully in connection with the defence,
negotiation or settlement of any Claim subject to this clause 9. 

  

	9.6.	The provisions of this clause 9 shall survive the termination for whatsoever reason of this Agreement. 

  

	9.7.	IN NO EVENT WILL EITHER PARTY BE LIABLE FOR LOST PROFITS, LOSS OF DATA, OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES HOWEVER CAUSED, ON ANY THEORY OF
LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF THIS AGREEMENT. THE FOREGOING LIMITATIONS WILL NOT APPLY TO AN AWARD OF ENHANCED DAMAGES
AVAILABLE UNDER THE PATENT LAWS FOR WILFUL PATENT INFRINGEMENT AND WILL NOT LIMIT EITHER PARTY’S OBLIGATIONS TO THE OTHER PARTY UNDER CLAUSES 7 AND 9 OF THIS AGREEMENT. 

  

	10.	TERM AND TERMINATION 

  

	10.1.	Unless earlier terminated in accordance with the provisions hereof, this Agreement shall expire on a country-by-country basis upon the expiration of the last-to-expire patent or
patent application within the Patents in the applicable country. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	10.2.	Either party shall have the right (but not the obligation) to terminate this Agreement and the Licence (if granted) hereunder by serving written notice (effective immediately) on
the other (“the party in breach”), in any of the following events: 

  

	10.2.1.	if a petition for bankruptcy or the equivalent under local law shall be filed against the party in breach, or if the party in breach shall make any assignment for the benefit of its
creditors, or if a receiver, custodian, liquidator, assignee, trustee, sequestrator (or other similar official) has been appointed over the property or a substantial portion thereof of the party in breach, or if the party in breach shall seek
protection under any laws or regulations, the effect of which is to suspend or impair the rights of any or all of its creditors or to impose a moratorium on such creditors or if the party in breach is wound-up or enters into insolvency or if
anything analogous to any of the foregoing mentioned in this clause 10.2.1 under the law of any jurisdiction occurs in relation to the party in breach; or 

  

	10.2.2.	if the party in breach has committed a material breach hereof and has failed to cure such breach within 60 (sixty) days (or 120 (one hundred and twenty) days in the case of a breach
of the Company’s obligations under clause 6.1) after receipt of a written notice from the non-breaching party identifying such breach; 

  

	    	In such event, this Agreement and the Licence (if granted) hereunder shall be terminated forthwith upon receipt of notice as aforesaid. Termination of this Agreement shall be
without prejudice to the rights and obligations of the parties hereto accruing up to and including the date of such termination. 

  

	10.3.	Any amount payable hereunder by one of the parties to the other, which has not been paid by its due date of payment, shall bear interest from its due date of payment until the date
of actual payment, at the rate of 3% (three percent) per annum in excess of the average LIBOR rate for US Dollar deposits for a period of 3 (three) months prevailing from time to time during the period of arrears. 

  

	10.4.	Without derogating from clause 10.2 above, Yeda shall have the right (but not the obligation) to terminate this Agreement and the Licence hereunder by serving written notice
(effective immediately) on the Company in the event that Biolex fails to comply with its payment obligations under the Master Agreement and fails to cure such breach within 14 (fourteen) days after receipt of a written notice from Yeda identifying
such breach, all without, derogating from such payment obligations of Biolex which shall remain in full force and effect. 

  

	10.5.	The Company shall have the right to terminate this Agreement and the License hereunder at will by at least sixty (60) days’ prior written notice to Yeda.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	10.6.	Upon termination of this Agreement, other than pursuant to clause 10.1 above, the Company: (i) shall deliver to Yeda all tables, graphs, diagrams, specifications and other
documentation or media in the Company’s possession, power or control containing the Yeda Information or any part thereof whether received or generated by the Company pursuant to this Agreement or the Prior Agreement; and (ii) shall not be
entitled to exploit any of the Patents or otherwise make any use of the Yeda Information. Such termination shall not relieve the parties of any obligations to make payments thereunder which shall have accrued prior to such termination.

  

	10.7.	Subsequent to expiration of this Agreement pursuant to clause 10.1 above, the Company: (i) shall have no liability to Yeda for payment hereunder in respect of the Licence or
the Company’s right to use the Yeda Information as described herein; and (ii) shall have a perpetual, irrevocable, royalty-free licence under the Yeda Information to research, develop, make, use, sell, offer for sale, import, and otherwise
exploit Products; provided, that Company shall continue to keep confidential and secret such Yeda Information pursuant to the surviving terms of this Agreement. 

  

	10.8.	The following clauses, together with any definitions used therein, shall survive any expiration or termination of this Agreement: clauses 7, 9, 10.8, 11, 12, 13, 14, 15, 16 and 17.
For the removal of doubt, save only in the case of termination of this Agreement by the Company pursuant to clause 10.2 above due to a material breach of this Agreement by Yeda, the payment obligations of Biolex under the Master Agreement shall
remain in full force and effect. 

  

	11.	ENTIRE AGREEMENT 

  

	    	This Agreement constitutes the entire agreement between the parties with respect to the subject-matter hereof. Any addition or amendment to this Agreement shall not be effective
unless in writing signed by the authorised signatories of both parties. 

  

	12.	GOVERNING LAW 

  

	    	This Agreement shall be governed in all respects by the laws of the State of Israel. Any disputes relating to the rights and obligations of the Parties under this Agreement may be
submitted to the courts of competent jurisdiction located in the State of Israel, and each Party hereby submits to the non-exclusive jurisdiction of such courts with respect to any such dispute, hereby waives any objection to the Israeli courts on
the grounds of inconvenient forum or otherwise and agrees that a judgment of an Israeli court will be conclusive and binding on it and may be enforced against it in the courts of any other jurisdiction. The Company hereby irrevocably appoints
Goldfarb, Levy, Eran & Co. (Europe-Israel Tower, 2 Weizmann Street, Tel Aviv 64239 Israel) as its agent for service of process in relation to any suit or proceedings before the Israeli courts in connection with any disputes relating to this
Agreement as aforesaid and agrees to maintain such agent for service of process in Israel for the entire period of this Agreement and 7 (seven) years thereafter. The Company agrees that the process 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	 	 
by which any suit or proceedings are begun in Israeli courts may be served on it to its agent for service as aforesaid. 

  

	13.	NOTICES 

  

	13.1.	Notices to be given hereunder may be given by telecopier or, if unavailable, as required by clause 13.2 below. If notice is sent by telecopier, it shall be deemed to have been
served 24 (twenty-four) hours after transmission. All notices given by telecopier shall be confirmed by letter dispatched in the manner provided in clause 13.2 below within 24 (twenty-four) hours of transmission. 

  

	13.2.	Any other notices to be given hereunder shall be served on a party by prepaid express registered letter (or nearest equivalent) to its address given herein or such other address as
may from time to time be notified for this purpose and any notice so served shall be deemed to have been served within 7 (seven) days after the time at which such notice was posted and, in proving such service, it shall be sufficient to prove that
the notice was properly addressed and posted. 

  

	14.	TAXES 

  

	    	Any stamp duty that may become due under the Israeli Stamp Duty Law, 1961 in connection with the execution of this Agreement will be borne by the Company and Yeda in equal shares.
Each party shall reimburse the other party, against submission of appropriate tax invoices, all amounts of value-added tax imposed on such other party in connection with the transactions under this Agreement. Each Party agrees to assist the other
Party, at the other Party’s request and expense, in claiming exemption, to the extent reasonably possible, under any applicable tax treaty, from the imposition on such other party of such taxes, provided that by so doing the party assisting
will not increase its own tax liability or waive any right to reimbursement from the other party as hereinbefore provided. 

  

	15.	MISCELLANEOUS 

  

	15.1.	The headings in this Agreement are intended solely for convenience or reference and shall be given no effect in the interpretation of this Agreement. 

  

	15.2.	This Agreement may be signed in any number of counterparts, no one of which need be signed by more than one party, and all such copies, when duly executed, shall be considered one
and the same document. 

  

	15.3.	 No waiver by any party hereto, whether express or implied, of its rights under any provision of this Agreement shall constitute a waiver of such party’s rights
under such provisions at any other time or a waiver of such party’s rights under any other provision of this Agreement. No failure by any party hereto to take any action against any breach of this Agreement or 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	 	 
default by another party hereto shall constitute a waiver of the former party’s rights to enforce any provision of this Agreement or to take action
against such breach or default or any subsequent breach or default by such other party. 

  

	15.4.	Subject to clause 15.4.2 below: 

  

	15.4.1.	this Agreement hereby terminates and supersedes, in its entirety, that certain Research Agreement dated as of June 1, 1999, as amended, as set forth in Appendix 1 hereto
(“the Prior Agreement”). In consideration of the rights and obligations set forth herein and in the Master Agreement: 

  

	 	(i)	Yeda hereby waives and forever discharges (and shall take reasonable steps to cause the Institute to waive and discharge) the Company, Biolex, and their respective assigns, and
successors, directors and officers (each, “a Company Entity”), from any claims that Yeda or the Institute, respectively, may have against any Company Entity arising out of, or relating to the Company’s performance, breach, rights, or
obligations under the Prior Agreement at any time prior to the Effective Date, except as otherwise expressly provided in clauses 7, 9. and 10.6 above (each, “a Prior Agreement Claim”), including without limitation any claim for payment or
amounts owed by Company, any Company Entity or stockholder in connection with the acquisition of Company by Biolex, but excluding (i) claims under clauses 7 and 9 with respect to breaches committed under the Prior Agreement with respect to the
matters governed by the said clauses 7 and 9 and (ii) the following payments: (1) the upfront payment of US $[***] ([***] United States dollars) payable by Biolex to Yeda on the Effective Date pursuant to paragraph (i) of Appendix 4
to the Master Agreement, and (2) the sum of €[***] ([***] Euros) payable by Biolex to Yeda, on behalf of the Company and its shareholders immediately prior to the Effective Date and representing the payment due to Yeda from the Company and
its shareholders relating to Biolex’s acquisition of the Company. In the event that the Institute initiates a Prior Agreement Claim, Yeda shall take reasonable steps to cause the Institute to discontinue or abandon such claim.

  

	 	(ii)	The Company hereby waives and forever discharges Yeda the Institute, and their respective assigns, successors, directors and officers (each, “a Yeda Entity”), from any
claims that the Company may have against any Yeda Entity arising out of, or relating to Yeda’s performance, breach, rights, or obligations under the Prior Agreement at any time prior to the Effective Date. 

  

	15.4.2.	Nothing herein contained shall derogate from the obligations of the Company to pay all patent costs and expenses incurred in connection with the Patents prior to the completion of
the Settlement Agreement (including, without limitation, in respect of the interference proceedings referred to in Recital C of the Master Agreement) incurred prior to the completion of the Settlement Agreement and the approval thereof by the
relevant US tribunal. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	15.4.3.	The rights and obligations of this Section 15.4 shall be binding upon and inure to the benefit of the successors and assigns of the parties hereto. 

  

	16.	GUARANTEE 

  

	16.1.	Biolex irrevocably and unconditionally guarantees to Yeda, the due and punctual observance and performance of all the obligations of the Company pursuant to clause 9 of this Licence
Agreement and agrees to pay to Yeda from time to time on demand any and every sum or sums of money which the Company is at any time liable to pay to Yeda under or pursuant to clause 9 of the Licence Agreement and which has become due and payable but
has not been paid at the time such demand is made. Biolex further irrevocably and unconditionally guarantees to Yeda, the due observance and performance of the all the obligations of the Company pursuant to clause 6 of the License Agreement.

  

	16.2.	The obligations of Biolex herein contained shall constitute and be continuing obligations notwithstanding any settlement of account or other matter or thing and shall not be
considered satisfied by any intermediate payment or satisfaction of all or any of the obligations of the Company under clauses 6 and/or 9 of the Licence Agreement and shall continue in full force and effect until final payment in full of all amounts
owing by the Company under clause 9 of the Licence Agreement and complete performance of the Company’s actual and contingent obligations under clauses 6 and 9 of the Licence Agreement. 

  

	16.3.	Neither the obligations of Biolex herein contained nor the rights, powers and remedies conferred upon Yeda by Biolex by this guarantee or by law shall be discharged, impaired or
otherwise affected by: 

  

	16.3.1.	the winding-up, dissolution, administration or re-organisation of the Company or any other person or any change in the Company’s status, function, control or ownership;

  

	16.3.2.	any of the obligations of the Company or any other person under the Licence Agreement being or becoming illegal, invalid, unenforceable or ineffective in any respect;

  

	16.3.3.	time or other indulgence being granted or agreed to be granted to the Company in respect of its obligations under the Licence Agreement; 

  

	16.3.4.	any amendment to, or any variation, waiver or release of, any obligation of the Company under the Licence Agreement, or under any such other security; 

  

	16.3.5.	any other act, event or omission which, but for this clause 16.3 might operate to discharge, impair or otherwise affect any of the obligations of Biolex herein contained or any of
the rights, powers or remedies conferred upon Yeda by this guarantee or by law. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

	16.4.	Yeda shall not be obliged before exercising any of the rights, powers or remedies conferred upon it by Biolex by this guarantee or by law: 

  

	16.4.1.	to make any demand of the Company; 

  

	16.4.2.	to take any action or obtain judgment in any court against the Company; or 

  

	16.4.3.	to make or file any claim or proof in a winding-up, bankruptcy or dissolution of the Company. 

  

	16.5.	Without derogating from any other provisions of this guarantee which exclude the application of, or constitute a waiver by Biolex of, certain defences or rights under the Guarantee
Law, 1967 (“the Guarantee Law”) (which defences or rights would, but for such provision, have been available to Biolex), Biolex hereby waives all rights and defences under the Guarantee Law and confirms that the provisions of the Guarantee
Law affording such rights or defences to a guarantor shall not apply to this guarantee. 

  

	17.	APPLICABLE LAW AND JURISDICTION FOR GUARANTEE 

  

	    	The guarantee pursuant to clause 16 above (“the Guarantee”) shall be governed by, enforced, and shall be construed in accordance with the laws of the State of Israel. Any
disputes relating to the rights and obligations of Yeda and Biolex under the Guarantee may be submitted to the courts of competent jurisdiction located in the State of Israel, and each of Yeda and Biolex hereby submits to the non-exclusive
jurisdiction of such courts with respect to any such dispute, hereby waives any objection to the Israeli courts on the grounds of inconvenient forum or otherwise and agrees that a judgment of an Israeli court will be conclusive and binding on it and
may be enforced against it in the courts of any other jurisdiction. Biolex hereby irrevocably appoints Goldfarb, Levy, Eran & Co. (Europe-Israel Tower, 2 Weizmann Street, Tel Aviv 64239 Israel) as its agent for service of process in
relation to any suit or proceedings before the Israeli courts in connection with any disputes relating to the Guarantee as aforesaid and agrees to maintain such agent for service of process in Israel for the entire period of this Agreement and 7
years thereafter. Biolex agrees that the process by which any suit or proceedings are begun in Israeli courts may be served on it to its agent for service as aforesaid. Without derogating from the provisions hereinbefore relating to the appointment
and maintenance of agent for service and to service of process for Biolex on such agent, it is agreed that the provisions of clause 13 of the Licence Agreement shall apply to the Guarantee, and, the address of Biolex for service of such notices
shall be the address of Biolex for notices under the Master Agreement. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 IN WITNESS WHEREOF, the parties have signed this Agreement on the date first mentioned above. 
  

									
	For	 	YEDA RESEARCH AND	 		 	for LEMNAGENE, S.A.
		 	DEVELOPMENT COMPANY LTD.	 		 		 	
					
	By:	 	 /s/ Isaac Shariv
	 		 	By:	 	 /s/ Illegible

					
	Title:	 	C.E.O	 		 	Title:	 	Directeur Général
				
	for BIOLEX INCORPORATED (as to clauses 16 and 17 only)	 		 		 	
					
	By:	 	 /s/ Dale Sander
	 		 		 	
					
	Title:	 	Chief Financial Officer	 		 		 	

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 SCHEDULE A(1) 
 The Existing Patents 
 Edelman Patent Families: 
 Title: Transgenic Lemnaceae 
  

			
	Inventors:	  	EDELMAN, Meir; PERL, Avihai; FLAISHMAN, Moshe A.;
		  	BLUMENTHAL, Amnon

  

									
	 Country
	  	 Application No.
 Patent No.
	  	Appln. Date	  	Pub. No
	 Patent Cooperation Treaty
	  	PCT/1L97/00328	  	10/10/1997	  	WO99/19497
	 Patent Cooperation Treaty
	  	PCT/IL98/00487	  	8/10/1998	  	WO99/19498
	 Australia
	  	94572/98	  	8/10/1998	  	
		  	759570	  		  	
				
	 Australia
	  	2003200730	  	8/10/1998	  	
	 Australia
	  	2003200732	  	8/10/1998	  	
	 Australia
	  	2003200734	  	8/10/1998	  	
	 Canada
	  	2,312,008	  	8/10/1998	  	
	 European Patent Office
	  	98947760.9	  	8/10/1998	  	1 021 552
	 Israel
	  	135543	  	8/10/1998	  	
	 U.S.A.
	  	09/529,172	  	8/10/1998	  	
					
	Title:	 	Transgenic Lemnaceae	  		  		  	
					
	Inventors:	 	EDELMAN, Meir; VUNSH, Ron	  		  		  	
				
	 Country
	  	 Application No.
	  	Appln. Date	  	Pub. No.
	 U.S.A.
	  		  	1/6/2004	  	

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 SCHEDULE A(2) 
 The Existing Technology 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 APPENDIX 1 
 The Prior Agreements 
  

	1.	Research Agreement between Yeda and Rhone-Poulenc Agro dated June 1, 1999 

  

	2.	Letter for Extension of Licence Negotiation Period dated January 7, 2002 

  

	3.	Letter for Licence Negotiation, dated February 25, 2002 

  

	4.	Amendment to Aventis CropScience SA/Yeda Research Agreement dated June 14, 2002 

  

	5.	Amendment No. 2 to Aventis CropScience SA/Yeda Research Agreement dated December 23, 2002 

  

	6.	Assignment and Licence Agreement, between Yeda, LemnaGene LLC and Bayer Crop Science SA (known as Aventis CropScience) dated January 31, 2003 

  

	7.	Letter to Amend Licence Agreement, dated May 26, 2003 

  

	8.	Amendment No. 2 to the Licence Agreement dated September 22, 2003 

  

	9.	Assignment and Assumption Agreement between LemnaGene LLC and the Company (with consent by Yeda) dated November 30, 2003 

  

	10.	Second Extension to Research Agreement between Yeda and the Company dated October 20, 2004 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.License Agreement between Epicyte Pharmaceutical, Inc. & The Scripps Research

 Exhibit 10.7 
 LICENSE AGREEMENT 
 by and between 
 THE SCRIPPS RESEARCH INSTITUTE, 
 a California nonprofit 
 public benefit corporation 
 and 

 EPIcyte Pharmaceutical, Inc., 
 a California corporation 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 TABLE OF CONTENTS 
  

									
	 	  	 	  	 	 	 	  	Page
	 1.    
	  	 Definitions
	  	1
		  	 1.1
	  	 Affiliate
	  	1
		  	 1.2
	  	 Confidential Information
	  	1
		  	 1.3
	  	 Medical Field
	  	2
		  	 1.4
	  	 All Fields
	  	2
		  	 1.5
	  	 Scripps Patent Rights
	  	2
		  	 1.6
	  	 Licensed Product
	  	2
		  	 1.7
	  	 Diagnostic and OTC Uses
	  	2
		  	 1.8
	  	 Valid Claim
	  	2
		  	 1.9
	  	 Net Sales
	  	3
			
	 2.
	  	 License Terms and Conditions
	  	3
		  	 2.1
	  	 Grant of License
	  	3
		  	 2.2
	  	 Reversion of Rights in Fields other than the Medical Field
	  	3
		  	 2.3
	  	 Initial License Fee
	  	3
		  	 2.4
	  	 Royalties
	 		  	3
		  		  	 2.4.1
	 	 Percentage Royalty
	  	3
		  		  	 2.4.2
	 	 Minimum Royalty
	  	4
		  		  	 2.4.3
	 	 Royalty Credits for Third Party License Costs
	  	4
		  	 2.5
	  	 Quarterly Payments.
	  	5
		  		  	 2.5.1
	 	 Sales by EPIcyte
	  	5
		  		  	 2.5.2
	 	 Sales by Sublicensees
	  	5
		  	 2.6
	  	 Term of License
	  	5
		  	 2.7
	  	 Sublicense
	  	5
		  	 2.8
	  	 Duration of Royalty Obligations
	  	6
		  	 2.9
	  	 Reports
	  	6
		  	 2.10
	  	 Records
	  	6
		  	 2.11
	  	 Foreign Sales
	  	6
		  	 2.12
	  	 Withholdings
	  	6
			
	 3.
	  	 Patent Matters.
	  	7
		  	 3.1
	  	 Patent Prosecution acid Maintenance
	  	7
		  	 3.2
	  	 Information to EPIcyte
	  	7
		  	 3.3
	  	 Patent Costs
	  	7
		  	 3.4
	  	 Ownership
	  	8
		  	 3.5
	  	 Scripps Right to Pursue Patent
	  	8
		  	 3.6
	  	 Infringement Actions
	  	8
		  		  	 3.6.1
	 	 Prosecution and Defense of Infringements
	  	8
		  		  	 3.6.2
	 	 Allocation of Recovery
	  	8
			
	 4.
	  	 Obligations Related to Commercialization
	  	8

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 i 

									
		  	 4.1
	  	 Commercial Development Obligation
	  	8
		  	 4.2
	  	 Governmental Approvals and Marketing of Licensed Products
	  	9
		  	 4.3
	  	 Indemnity
	  	9
		  	 4.4
	  	 Patent Marking
	  	9
		  	 4.5
	  	 No Use of Name
	  	10
		  	 4.6
	  	 U.S. Manufacture
	  	10
		  	 4.7
	  	 Foreign Registration
	  	10
			
	 5.    
	  	 Limited Warranty
	  	10
			
	 6.
	  	 Interests in Intellectual Property Rights
	  	10
		  	 6.1
	  	 Preservation of Title
	  	10
		  	 6.2
	  	 Royalty-free License to Improvements
	  	10
		  	 6.3
	  	 Governmental Interest
	  	10
		  	 6.4
	  	 Reservation of Rights
	  	11
			
	 7.
	  	 Confidentiality and Publication
	  	11
		  	 7.1
	  	 Treatment of Confidential Information
	  	11
		  	 7.2
	  	 Publications
	  	11
		  	 7.3
	  	 Publicity
	  	11
			
	 8.
	  	 Term and Termination.
	  	11
		  	 8.1
	  	 Term
	  	11
		  	 8.2
	  	 Termination Upon Default
	  	11
		  	 8.3
	  	 Termination Upon Bankruptcy or Insolvency
	  	12
		  	 8.4
	  	 Termination by EPIcyte
	  	12
		  	 8.5
	  	 Rights Upon Expiration
	  	12
		  	 8.6
	  	 Rights Upon Termination
	  	12
		  	 8.7
	  	 Work-in-Progress
	  	13
			
	 9.
	  	 Assignment; Successors.
	  	13
		  	 9.1
	  	 Assignment
	  	13
		  	 9.2
	  	 Binding Upon Successors and Assigns
	  	13
			
	 10.
	  	 General Provisions
	  	13
		  	 10.1
	  	 Independent Contractors
	  	13
		  	 10.2
	  	 Arbitration
	  	13
		  		  	 10.2.1
	  	 Location
	  	13
		  		  	 10.2.2
	  	 Selection of Arbitrators
	  	14
		  		  	 10.2.3
	  	 Discovery
	  	14
		  		  	 10.2.4
	  	 Case Management
	  	14
		  		  	 10.2.5
	  	 Remedies
	  	14
		  		  	 10.2.6
	  	 Expenses
	  	14
		  		  	 10.2.7
	  	 Confidentiality
	  	14
		  	 10.3
	  	 Entire Agreement; Modification
	  	14
		  	 10.4
	  	 California Law
	  	15
		  	 10.5
	  	 Headings
	  	15

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 ii 

									
		  	 10.6
	  	 Severability
	  	15
		  	 10.7
	  	 No Waiver
	  	15
		  	 10.8
	  	 Name
	  	15
		  	 10.9
	  	 Attorneys’ Fees
	  	15
		  	 10.10
	  	 Notices
	  	15
		  	 10.11
	  	 Compliance with U.S. Laws
	  	16

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 iii 

 LICENSE AGREEMENT 
 This License Agreement is entered into and made effective as of this 9th day of October, 1997, by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“Scripps”)
located at 10550 North Torrey Pines Road, La Jolla, California 92037, and EPICYTE PHARMACEUTICAL, INC., a California corporation (“EPIcyte”) located at 8445 Camino Santa Fe, Suite 102, San Diego, California 92121, with respect to the facts
set forth below. 
 RECITALS 
 A. Scripps is engaged in fundamental scientific biomedical and biochemical research including research relating to production in plants of transgenic proteins. 
 B. EPIcyte is engaged in research and development of molecules for diagnosis, prophylaxis, and treatment of human and animal diseases, and for personal
care and nutraceutical applications, and environmental, industrial and agricultural purposes. 
 C. Scripps has disclosed to EPIcyte certain
patents and patent applications related to expression of antibodies and other immunoglobulin related molecules in plants, a list of which is attached hereto as Exhibit A and incorporated herein by reference (the “Plantibodies Technology
Patents”). 
 D. Scripps has the exclusive right to grant a license under the Plantibodies Technology Patents subject to certain rights
of the U.S. Government to use such technology for its own purposes, resulting from the receipt by Scripps of certain funding from the U.S. Government. 
 E. Scripps desires to grant to EPIcyte, and EPIcyte wishes to acquire, an exclusive worldwide right and license under the Plantibodies Technology Patents subject to the terms and conditions set forth herein, with a
view to developing and marketing products within All Fields (as defined below). 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual covenants and conditions set forth herein, Scripps and EPIcyte hereby agree as follows: 
 1. Definitions. Capitalized terms shall have the meaning set forth below. 
 1.1 Affiliate. The term “Affiliate” shall mean any entity which directly or indirectly controls, is controlled by or is under common
control with EPIcyte. The term “control” as used herein means the possession of the power to direct or cause the direction of the management and the policies of an entity, whether through the ownership of a majority of the outstanding
voting securities or by contract or otherwise. 
 1.2 Confidential Information. The term “Confidential Information” shall
mean any and all proprietary or confidential information of Scripps or EPIcyte which may be exchanged between the parties at any time and from time to time during the term 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 
of this Agreement. Information shall not be considered confidential to the extent that it: 
 (a) Is publicly disclosed through no fault of any party hereto, either before or after it becomes known to the receiving party; or 
 (b) Was known to the receiving party prior to the date of this Agreement, which knowledge was acquired independently and not from another party hereto
(or such party’s employees); or 
 (c) Is subsequently disclosed to the receiving party in good faith by a third party who has a right
to make such disclosure; or 
 (d) Has been published by a third party as a matter of right. 
 1.3 Medical Field. The term “Medical Field” shall mean human and animal diagnostic, prophylactic and therapeutic treatments and personal
care products and shall specifically exclude any agricultural applications of products, but shall not exclude agricultural means of producing products in the Medical Field. 
 1.4 All Fields. The term “All Fields” shall mean any and all fields of application, including but not limited to the Medical Field,
personal care, nutraceutical, environmental, industrial and agricultural applications. 
 1.5 Scripps Patent Rights. The term
“Scripps Patent Rights” shall mean rights arising out of or resulting from (i) any and all U.S. and foreign patent applications and patents set forth in Exhibit A, (ii) the patents proceeding from such applications,
(iii) divisionals, continuations, reissues, reexaminations, and extensions of any patent or application set forth in (i)-(ii) above. 
 1.6 Licensed Product. The term “Licensed Product” shall mean any product which cannot be developed, manufactured, used or sold without (i) infringing one or more Valid Claims under Scripps Patent Rights. 
 1.7 Diagnostic and OTC Uses. The term “Diagnostic and OTC Uses” shall mean the use of a Licensed Product primarily for diagnosing a
condition or the use of a Licensed Product as a remedy or for therapeutic or other purposes where such use does not require prescription or is sold “over-the-counter” (OTC). 
 1.8 Valid Claim. The term “Valid Claim” shall mean either: (a) a claim in any unexpired patent within the Scripps Patent Rights
which has not been held invalid by a non-appealed or unappealable decision rendered by a court or other appropriate governmental body of competent jurisdiction; or (b) a bona fide claim in any patent application within the Scripps Patent
Rights, provided such claim has not been pending longer than the later of (i) seven (7) years from the date of filing of the earliest asserted priority patent application; or (ii) seven (7) years from the date of the request for
examination in a country in which such a request is necessary. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 2 

 1.9 Net Sales. The term “Net Sales” shall mean the gross amount invoiced by EPIcyte, or
its Affiliates and sublicensees, or any of them, on all sales of Licensed Products, less (i) discounts actually allowed, (ii) credits for claims, allowances, retroactive price reductions or returned goods, (iii) actual freight and
insurance charges (iv) reasonable and customary cash, quantity and trade discounts and other price reduction programs, and (v) customs, duties, surcharges, sales taxes or other governmental charges actually paid in connection with sales of
Licensed Products (but excluding what is commonly known as income taxes). For purposes of determining Net Sales, a sale shall be deemed to have occurred when an invoice therefor shall be generated or the Licensed Product shipped for delivery. Sales
of Licensed Products by EPIcyte, or an Affiliate or sublicensee of EPIcyte to any Affiliate or sublicensee which is a reseller thereof shall be excluded, and only the subsequent sale of such Licensed Products by Affiliates or sublicensees of EPIcyte
to unrelated parties shall be deemed Net Sales hereunder. 
 2. License Terms and Conditions. 
 2.1 Grant of License. Scripps hereby grants to EPIcyte an exclusive, worldwide license, including the right to sublicense, under Scripps Patent
Rights, to make, to have made, to use, and to sell Licensed Products in All Fields, subject to the terms of this Agreement. 
 2.2
Reversion of Rights in Fields other than the Medical Field. The grant of license in All Fields other than the Medical Field shall be subject to reversion to Scripps if EPIcyte is in default of its Minimum Royalty Payments as described in
Section 2.4.2 and such default is not fully cured within sixty (60) days after receipt of a written notice requesting the payment of such amount, Scripps may terminate EPIcyte’s rights under this Agreement to All Fields other than the
Medical Field, but will not otherwise affect EPIcyte’s rights under this Agreement in the Medical Field. 
 2.3 Initial License
Fee. In partial consideration for the exclusive license granted pursuant to Section 2.1 hereof, EPIcyte, pursuant to a Series A Preferred Stock Purchase Agreement attached hereto as Exhibit B and incorporated herein by this reference (a
“Stock Purchase Agreement”), promptly after the effective date hereof shall issue to Scripps 306,580 shares of EPIcyte’s Series A Preferred Stock. The licence fee described in this Section is consideration for the grant and
continuation of the license hereunder, and Scripps shall have no obligation to return any portion of such license fee, notwithstanding any failure by EPIcyte to develop any Licensed Product or market any Licensed Product commercially, and
notwithstanding the volume of sales of any such Licensed Product. 
 2.4 Royalties. 
 2.4.1 Percentage Royalty. As additional consideration for the exclusive license granted pursuant to Section 2.1 hereof, EPIcyte shall pay to
Scripps a continuing royalty on a country-by-country basis based upon its Net Sales of Licensed Products (subject to the other provisions of this Section 2). The royalty rate shall be determined as follows: 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 3 

 (a) For Licensed Products in the Medical Field, other than those sold for Diagnostic and OTC Uses, the
royalty rate shall be [***] percent ([***]%) based on EPIcyte’s Net Sales of such Licensed Products. 
 (b) For Licensed Products in
the Medical Field sold for Diagnostic and OTC Uses the royalty rate shall be [***] percent ([***]%) based on EPIcyte’s Net Sales of such Licensed Products. 
 (c) For Licensed Products in All Fields except the Medical Field the royalty rate shall be [***] percent ([***]%) based on EPIcyte’s Net Sales of such Licensed Products. 
 (d) EPIcyte’s royalty obligations under sub-sections 2.3.1(a) 2.3.1 (b) and 2.3.1(c) shall terminate on a country by country basis upon the
expiration of the last to expire of Scripps Patent Rights covering the Licensed Product in each such country. 
 2.4.2 Minimum
Royalty. From and after September 1, 2000, in order to maintain the license granted hereunder in force for All Fields except for the Medical Field EPIcyte shall pay to Scripps a minimum annual royalty. The minimum annual royalty for the
twelve (12) month period beginning with such date shall be [***] Dollars ($[***]), and the amount of the minimum annual royalty payable for each subsequent twelve (12) month period during the term hereof shall be the greater of [***]
Dollars ($[***]) or [***] percent ([***]%) of the total royalties payable under this Agreement during the immediately preceding twelve (12) month period for products sold in All Fields except for the Medical Field. Any percentage royalties
earned and paid to Scripps pursuant to Section 2.4.1 hereof for any twelve (12) month period shall be credited against the minimum royalty payable for such period, and the payment of any shortfall between actual royalties paid and the
minimum annual royalty applicable to such twelve (12) month period shall be payable to Scripps within sixty (60) days after the last day of such twelve (12) month period. 
 2.4.3 Royalty Credits for Third Party License Costs. EPIcyte shall be entitled to a credit against royalties due hereunder of fifty percent
(50%) of any royalty paid to a third party by EPIcyte, its Affiliates or sublicensees which is necessary in order for EPIcyte or its Affiliates or sublicensees to sell any Licensed Product without infringing any patent or other rights of such
third party against any royalty accrued with respect to such Licensed Product. In the event that EPIcyte makes such payments on any single Licensed Product to more than one third party, EPIcyte shall be allowed to aggregate such payments against any
royalty accrued with respect to such Licensed Product, provided that (a) the royalty due with respect to such Licensed Product shall not be reduced below [***] percent ([***]%) of Net Sales where the Licensed Product is sold for uses in the
Medical Field other than for Diagnostic or OTC Uses, (b) the royalty due with respect to such Licensed Product shall not be reduced below [***] percent ([***]%) of Net Sales where the Licensed Product is sold for uses in All Fields other than
the Medical Field or in the Medical Field for Diagnostic or OTC Uses. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 4 

 2.5 Quarterly Payments. 
 2.5.1 Sales by EPIcyte. With regard to Net Sales made by EPIcyte or its Affiliates, royalties shall be payable by EPIcyte quarterly, within sixty
(60) days after the end of each calendar quarter, based upon the Net Sales of Licensed Products during such preceding calendar quarter, commencing with the calendar quarter in which the first commercial sale of any Licensed Product is made.

 2.5.2 Sales by Sublicensees. With regard to Net Sales made by sublicensees of EPIcyte or its Affiliates, royalties shall be
payable by EPIcyte quarterly, within ninety (90) days after the end of each calendar quarter, based upon the Net Sales of Licensed Products by such sublicensee during such preceding calendar quarter, commencing with the calendar quarter in
which the first commercial sale of any Licensed Product is made by such sublicensee. 
 2.6 Term of License. Unless terminated sooner
in accordance with the provisions of this Agreement, the term of this license shall expire when the last of the royalty obligations set forth has expired. Notwithstanding the foregoing, if applicable government regulations require a shorter term
and/or a shorter term of exclusivity than provided for herein, then the term of this License Agreement shall be so shortened or this License Agreement shall be amended to provide for a non-exclusive license, and, in such event, the parties shall
negotiate in good faith to reduce appropriately the royalties payable as set forth under the section heading “Royalties” hereof. 
 2.7 Sublicense. EPIcyte shall have the sole and exclusive right to grant sublicenses to any party with respect to the rights conferred upon EPIcyte under this Agreement, provided, however, that any such sublicense shall be subject in
all respects to the restrictions, exceptions, royalty obligations, reports, termination provisions, and other provisions contained in this Agreement (but not including the payment of a license fee pursuant to Section 2.2 hereof). EPIcyte agrees
to forward to Scripps a copy of any and all sublicense agreements within thirty (30) days of the execution of such sublicense agreements by the parties thereto. EPIcyte shall pay Scripps, or cause its Affiliate or sublicensee to pay Scripps,
the same royalties on all Net Sales of such Affiliate or sublicensee the same as if said Net Sales had been made by EPIcyte. Each Affiliate and sublicensee shall report its Net Sales to Scripps through EPIcyte, which Net Sales shall be aggregated
with any Net Sales of EPIcyte for purposes of determining the Net Sales upon which royalties are to be paid to Scripps. 
 Except as set
forth below, any revenues, other than royalties, equity payments, and research and development payments, including costs for clinical testing due EPIcyte pursuant to the grant of a sublicense to a party not an Affiliate shall be reported to Scripps
by EPIcyte. EPIcyte shall pay to Scripps [***] percent ([***]%) of the first one million Dollars ($1,000,000) or part thereof, [***] percent ([***]%) of the second one million Dollars ($1,000,000) or part thereof, and [***] percent ([***]%) of any
additional sum of any such revenue for each sublicensing agreement. Revenues shall be limited to any up-front license fees and milestone payments received by EPIcyte pursuant to a sublicense of any rights granted EPIcyte hereunder. Monies paid to
EPIcyte exclusively to fund research and development, to fund clinical testing, or in the form of a loan, are not subject to any royalty to Scripps. Any monies received in the form of an equity investment in EPIcyte, shall not be subject to any
payment to Scripps. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 5 

 2.8 Duration of Royalty Obligations. The royalty obligations of EPIcyte as to each Licensed
Product shall terminate on a country-by-country basis concurrently with the expiration of the last to expire of Scripps Patent Rights utilized by or in such Licensed Product in each such country. 
 2.9 Reports. EPIcyte shall furnish to Scripps at the same time as each royalty payment is made by EPIcyte, a detailed written report of Net Sales
of the Licensed Products and the royalty due and payable thereon, including a description of any offsets or credits deducted therefrom, on a product-by-product and country-by-country basis, for the calendar quarter upon which the royalty payment is
based. 
 2.10 Records. EPIcyte shall keep, and cause its Affiliates and sublicensees to keep, full, complete and proper records and
accounts of all sales of Licensed Products in sufficient detail to enable the royalties payable on Net Sales of each Licensed Product to be determined. Scripps shall have the right to appoint an independent certified public accounting firm approved
by EPIcyte, which approval shall not be unreasonably withheld, to audit the records of EPIcyte, its Affiliates and sublicensees as necessary to verify the royalties payable pursuant to this Agreement. EPIcyte, its Affiliates and sublicensees shall
pay to Scripps an amount equal to any additional royalties to which Scripps is entitled as disclosed by the audit, plus interest thereon at the rate of one and one-half percent (1.5%) per month. Such audit shall be at Scripps’ expense;
provided, however, that if the audit discloses that Scripps was underpaid royalties with respect to any Licensed Product by at least five percent (5%) for any twelve month period, then EPIcyte, its Affiliates or sublicensee, as the case may be
shall reimburse Scripps for any such audit costs. Scripps may exercise its right of audit as to each of EPIcyte, its Affiliates or sublicensees no more frequently than once in any calendar year. The accounting firm shall disclose to Scripps only
information relating to the accuracy of the royalty payments. EPIcyte, its Affiliates and sublicensees shall preserve and maintain all such records required for audit for a period of three (3) years after the calendar quarter to which the
record applies. 
 2.11 Foreign Sales. The remittance of royalties payable on sales outside the United States shall be payable to
Scripps in United States Dollar equivalents at the official rate of exchange of the currency of the country from which the royalties are payable, as quoted in the Wall Street Journal for the last business day of the calendar quarter in which the
royalties are payable. If the transfer of or the conversion into the United States Dollar equivalents of any such remittance in any such instance is not lawful or possible, the payment of such part of the royalties as is necessary shall be made by
the deposit thereof, in the currency of the county where the sale was made on which the royalty was based to the credit and account of Scripps or its nominee in any commercial bank or trust company of Scripps’ choice located in that country,
prompt written notice of which shall be given by EPIcyte to Scripps. 
 2.12 Withholdings. The parties acknowledge that EPIcyte, its
Affiliates and sublicensees may be obligated to pay taxes, fees, assessments or other charges imposed by government authorities (the “Charges”) upon royalty payments payable in connection with the sale of Licensed Products. EPIcyte, shall
furnish Scripps with proof of payment of such tax together with official or other appropriate evidence issued by the applicable government authority. Any such tax actually paid on Scripps’ behalf shall be deducted from royalty payments due
Scripps. Affiliates and sublicensees shall deduct all Charges from such royalty payments and shall 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 6 

 
pay the Charges to the appropriate government authorities. EPIcyte shall promptly provide to Scripps any and all documents which may be reasonably necessary
for Scripps to obtain any credit to which it may be entitled with respect to the Charges. 
 3. Patent Matters. 
 3.1 Patent Prosecution acid Maintenance. From and after the date of this Agreement, the provisions of this Section 3 shall control the
prosecution and maintenance of any patent included within Scripps Patent Rights. Subject to the requirements, limitations and conditions set forth in this Agreement, Scripps shall direct and control (i) the preparation, filing and prosecution
of the United States and foreign patent applications within Scripps Patent Rights (including any interferences and foreign oppositions) and (ii) maintain the patents issuing therefrom. Scripps shall select the patent attorney, subject to
EPIcyte’s written approval, which approval shall not be unreasonably withheld. Both parties hereto agree that Scripps may, at its sole discretion, utilize Scripps’ Office of Patent Counsel in lieu of outside counsel for patent prosecution
and maintenance described herein, and the fees and expenses incurred by Scripps with respect to work done by such Office of Patent Counsel shall be paid as set forth below. EPIcyte shall have full rights of consultation with the patent attorney so
selected on all matters relating to Scripps Patent Rights. Scripps shall use its best efforts to implement all reasonable requests made by EPIcyte with regard to the preparation, filing, prosecution raid/or maintenance of the patent applications
and/or patents within Scripps Patent Rights. 
 3.2 Information to EPIcyte. Scripps shall keep EPIcyte informed with regard to the
patent application and maintenance processes. Scripps shall deliver to EPIcyte copies of all patent applications, amendments, related correspondence, and other related matters and shall make reasonable efforts to provide such documents prior to the
filing thereof. 
 3.3 Patent Costs. EPIcyte acknowledges and agrees that Scripps does not have independent funding to cover patent
costs, and that the license granted hereunder is in part in consideration for EPIcyte’s assumption of patent costs and expenses as described herein. EPIcyte shall pay for all expenses incurred by Scripps pursuant to Section 3.1 hereof. In
addition, EPIcyte agrees to reimburse Scripps for all patent costs and expenses paid or incurred by Scripps to date in connection with Scripps Patent Rights licensed hereunder. EPIcyte agrees to pay to Scripps the sum of fifteen thousand dollars
($15,000) within ninety (90) days of the execution of this Agreement and the remaining patent costs and expenses paid or incurred by Scripps as of the effective date of this agreement in connection with Scripps Patent Rights licensed hereunder
by April 15, 1998. For all patent expenses incurred by Scripps after the effective date of this Agreement EPIcyte agrees to pay all such past and future patent expenses directly or to reimburse Scripps for the payment of such expenses within
sixty (60) days after EPIcyte receives an itemized invoice therefor. In the event EPIcyte elects to discontinue payment for the filing, prosecution and/or maintenance of any patent application and/or patent within Scripps Patent Rights, any
such patent application or patent shall be excluded from the definition of Scripps Patent Rights and from the scope of the license granted under this Agreement, and all rights relating thereto shall revert to Scripps and may be freely licensed by
Scripps. EPIcyte shall give Scripps at least sixty (60) days’ prior written notice of such election. No such notice shall have any effect on EPIcyte’s obligations to pay expenses incurred up to the effective date of such election.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 7 

 3.4 Ownership. The patent applications filed and the patents obtained by Scripps pursuant to
Section 3.1 hereof shall be owned solely by Scripps, assigned to Scripps and deemed a part of Scripps Patent Rights. 
 3.5 Scripps
Right to Pursue Patent. If at any time during the term of this Agreement, EPIcyte’s rights with respect to Scripps Patent Rights are terminated, Scripps shall have the right to take whatever action Scripps deems appropriate to obtain or
maintain the corresponding patent protection at its own expense. If Scripps pursues patents under this Section 3.5, EPIcyte agrees to cooperate fully, including by providing, at no charge to Scripps, all appropriate technical data and executing
all necessary legal documents. 
 3.6 Infringement Actions. 
 3.6.1 Prosecution and Defense of Infringements. In order to maintain the license granted hereunder in force, EPIcyte shall have the first option
to prosecute or abate any and all infringements of any Scripps Patent Rights and shall have the first option to defend all charges of infringement arising as a result of the exercise of Scripps Patent Rights by EPIcyte, its Affiliates or
sublicensees, unless otherwise agreed to between Scripps and EPIcyte. EPIcyte may enter into settlements, stipulated judgments or other arrangements respecting such infringement, at its own expense, but only with the prior written consent of
Scripps, which consent shall not be unreasonably withheld. Scripps shall permit any action to be brought in its name if required by law, and EPIcyte shall hold Scripps harmless from any costs, expenses of liability respecting all such infringements
or charges of infringement. Scripps agrees to provide reasonable assistance of a technical nature which EPIcyte may require in any litigation arising in accordance with the provisions of this Section 3.7.1, for which EPIcyte shall pay to
Scripps a reasonable hourly rate of compensation. In the event EPIcyte fails to prosecute any such infringement, EPIcyte shall notify Scripps in writing promptly and Scripps shall have the right to prosecute such infringement on its own behalf. In
the event that EPIcyte fails to commence enforcement or otherwise terminates or resolves an alleged infringement within six months after EPIcyte has learned of the alleged infringement, Scripps shall have the right, but not the obligation, to bring
and control any such action using counsel of its own choice and at its own expense. If one party brings any such action or proceeding, the other party may join in the action in order to provide reasonable assistance and to share in the costs and
expenses associated with the action. 
 3.6.2 Allocation of Recovery. Any damages or other recovery from an infringement action
undertaken by EPIcyte pursuant to Section 3.7.1 shall first be used to reimburse the parties for the costs and expenses incurred in such action, and shall thereafter be allocated between the parties based upon the relative commercial damages
that would have been suffered. If EPIcyte fails to prosecute any such action to completion, then any damages or other recovery net of the parties’ costs and expenses incurred in such infringement action shall be the sole property of Scripps.

 4. Obligations Related to Commercialization. 
 4.1 Commercial Development Obligation. In order to maintain the license granted hereunder in force, EPIcyte shall use reasonable efforts and due diligence to develop Scripps Patent Rights which are licensed
hereunder into commercially viable 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 8 

 
Licensed Products, as promptly as is reasonably and commercially feasible, and thereafter to produce and sell reasonable quantities of Licensed Products.
EPIcyte shall keep Scripps generally informed as to EPIcyte’s progress in such development, production and sale, including its efforts, if any, to sublicense Scripps Patent Rights, and EPIcyte shall deliver to Scripps an annual written report
and such other reports as Scripps may reasonably request. The parties hereto acknowledge and agree that achievement of the milestones described in Exhibit C attached hereto on or before the dates set forth therein shall be evidence of compliance by
EPIcyte with its commercial development obligations hereunder for the time periods specified in Exhibit C. In the event Scripps has a reasonable basis to believe that EPIcyte is not using reasonable efforts and due diligence as required hereunder,
upon notice by Scripps to EPIcyte which specifies the basis for such belief, Scripps and EPIcyte shall negotiate in good faith to attempt to mutually resolve the issue. In the event Scripps and EPIcyte cannot agree upon any matter related to
EPIcyte’s commercial development obligations, the parties agree to utilize arbitration pursuant to Section 10.2 hereof in order to resolve the matter. If the arbitrator determines that EPIcyte has not complied with its obligations
hereunder either for the Medical Field or for All Fields other than the Medical Field as described in Exhibit C1.1 and C1.2, respectively, and such default is not fully cured within sixty (60) days after the arbitrator’s decision, Scripps
may terminate EPIcyte’s rights under this Agreement in the Field for which EPIcyte is deemed to be in default of its commercial development obligation. 
 4.2 Governmental Approvals and Marketing of Licensed Products. EPIcyte shall be responsible for obtaining all necessary governmental approvals for the development, production, distribution, sale and use of any
Licensed Product, at EPIcyte’s expense, including, without limitation, any safety studies. EPIcyte shall have sole responsibility for any warning labels, packaging and instructions as to the use of Licensed Products and for the quality control
for any Licensed Product. 
 4.3 Indemnity. EPIcyte hereby agrees to indemnify, defend and hold harmless Scripps and any parent,
subsidiary or other affiliated entity and their trustees, officers, employees, scientists and agents from and against any liability or expense arising from any product liability claim asserted by any party as to any Licensed Product or any claims
arising from the use of any Scripps Patent Rights pursuant to this Agreement. Such indemnity and defense obligation shall apply to any product liability or other claims, including without limitation, personal injury, death or property damage, made
by employees, subcontractors, sublicensees, or agents of EPIcyte, as well as any member of the general public. EPIcyte shall use its best efforts to have Scripps and any parent, subsidiary or other affiliated entity and their trustees, officers,
employees, scientists and agents named as additional insured parties on any product liability insurance policies maintained by EPIcyte , its Affiliates and sublicensees applicable to Licensed Products. 
 4.4 Patent Marking. To the extent required by applicable law, EPIcyte shall mark all Licensed Products or their containers in accordance with the
applicable patent marking laws. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 9 

 4.5 No Use of Name. The use of the name “The Scripps Research Institute”,
“Scripps”, or any variation thereof in connection with the advertising or sale of Licensed Products is expressly prohibited. 
 4.6
U.S. Manufacture. To the extent required by applicable United States laws, if at all, EPIcyte agrees that Licensed Products will be manufactured in the United States, or its territories, subject to such waivers as may be required, or
obtained, if at all, from the United States Department of Health and Human Services, or its designee. 
 4.7 Foreign Registration.
EPIcyte agrees to register this Agreement with any foreign governmental agency which requires such registration, and EPIcyte shall pay all costs and legal fees in connection therewith. In addition, EPIcyte shall assure that all foreign laws
affecting this Agreement or the sale of Licensed Products are fully satisfied. 
 5. Limited Warranty. Scripps hereby represents and
warrants that it has full right and power to enter into this Agreement. SCRIPPS MAKES NO OTHER WARRANTIES CONCERNING SCRIPPS PATENT RIGHTS COVERED BY THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE AS TO SCRIPPS PATENT RIGHTS, OR ANY LICENSED PRODUCT. SCRIPPS MAKES NO WARRANTY OR REPRESENTATION AS TO THE VALIDITY OR SCOPE OF SCRIPPS PATENT RIGHTS, OR THAT ANY LICENSED PRODUCT WILL BE FREE FROM AN INFRINGEMENT
ON PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY INFRINGING SCRIPPS PATENT RIGHTS COVERED BY THIS AGREEMENT. 
 6. Interests in Intellectual Property Rights. 
 6.1 Preservation of Title. Scripps shall retain
full ownership and title to Scripps Patent Rights licensed hereunder and shall use its reasonable best efforts to preserve and maintain such full ownership and title, subject to EPIcyte fully performing all of its obligations under this Agreement.

 6.2 Royalty-free License to Improvements. EPIcyte hereby grants to Scripps a non-exclusive, royalty-free license to any improvement
to Scripps Patent Rights developed by EPIcyte, to use for its own non-commercial research purposes. 
 6.3 Governmental Interest.
EPIcyte and Scripps acknowledge that Scripps has received, and expects to continue to receive, funding from the United States Government in support of Scripps’ research activities. EPIcyte and Scripps acknowledge and agree that their respective
rights and obligations pursuant to this Agreement shall be subject to Scripps’ obligations and the rights of the United States Government, if any, which arise or result from Scripps’ receipt of research support from the United States
Government, including without limitation, the grant by Scripps to the United States a non-exclusive, irrevocable, royalty-free license to Scripps Patent Rights licensed hereunder for governmental purposes. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 10 

 6.4 Reservation of Rights. Scripps reserves the right to use for any non-commercial research
purposes and the right to allow other nonprofit institutions to use for any non-commercial research purposes any Scripps Patent Rights licensed hereunder, without Scripps or such other institutions being obligated to pay EPIcyte any royalties or
other compensation. 
 7. Confidentiality and Publication. 
 7.1 Treatment of Confidential Information. The parties agree that during the term of this Agreement, and for a period of three (3) years after
this Agreement terminates, a party receiving Confidential Information of the other party will (i) maintain in confidence such Confidential Information to the same extent such party maintains its own proprietary industrial information,
(ii) not disclose such Confidential Information to any third party without prior written consent of the other party and (iii) not use such Confidential Information for any purpose except those permitted by this Agreement. 
 7.2 Publications. EPIcyte agrees that Scripps shall have a right to publish in accordance with its general policies. 
 7.3 Publicity. Except as otherwise provided herein or required by law, no party shall originate any publication, news release or other public
announcement, written or oral, whether in the public press, stockholders’ reports, or otherwise, relating to this Agreement or to any sublicense hereunder, or to the performance hereunder or any such agreements, without the prior written
approval of the other party, which approval shall not be unreasonably withheld. Scientific publications published in accordance with Section 7.2 of this Agreement shall not be construed as publicity governed by this Section 7.3.

 8. Term and Termination. 
 8.1 Term. Unless terminated sooner in accordance with the terms set forth herein, this Agreement, and the license granted hereunder, shall terminate as-provided in Section 2.6 hereof. 
 8.2 Termination Upon Default. Any one or more of the following events shall constitute an event of default hereunder: (i) the failure of a
party to pay any amounts when due hereunder and the expiration of sixty (60) days after receipt of a written notice requesting the payment of such amount; (ii) the failure of a party to perform any obligation required of its to be
performed hereunder, and the failure to cure within sixty (60) days after receipt of notice from the other party specifying in reasonable detail the nature of such default. Upon the occurrence of any event of default, the non-defaulting party
may deliver to the defaulting party written notice of intent to terminate, such termination to be effective upon the date set forth in such notice. 
 Such termination rights shall be in addition to and not in substitution for any other remedies that may be available to the non-defaulting party. Termination pursuant to this Section 8.2 shall not relieve the defaulting party from
liability and damages to the other party for breach of this Agreement. Waiver by either party of a single default or a succession of defaults shall not deprive such party of any right to terminate this Agreement arising by reason of any subsequent
default. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 11 

 8.3 Termination Upon Bankruptcy or Insolvency. This Agreement may be terminated by Scripps giving
written notice of termination to EPIcyte upon the filing of bankruptcy or bankruptcy of EPIcyte or the appointment of a receiver of any of EPIcyte’s assets, or the making by EPIcyte of any assignment for the benefit of creditors, or the
institution of any proceedings against EPIcyte under any bankruptcy law which proceeding is not dismissed within twenty (20) days. Termination shall be effective upon the date specified in such notice. 
 8.4 Termination by EPIcyte. Any provision herein notwithstanding, EPIcyte may terminate this Agreement, in its entirety or as to any particular
patent or patent application within the Scripps Patent Rights, or as to any particular Licensed Product, at any time by giving Scripps at least ninety (90) days prior written notice. From and after the effective date of a termination under this
Section 8.4 with respect to a particular patent or application, such patent(s) and patent application(s) in the particular country shall cease to be within the Scripps Patent Rights for all purposes of this Agreement, and all rights and
obligations of EPIcyte with respect to such patent(s) and patent application(s) shall terminate. From and after the effective date of a termination under this section 8.4 with respect to a particular Licensed Product, the license granted under
Section 2.1 above shall terminate with respect to such Licensed Product, and the same shall cease to be Licensed Product for all purposes of this Agreement. Upon a termination of this Agreement in its entirety under this Section 8.4, all
rights and obligations of the parties shall terminate, except as provided in Section 8.5 below. 
 8.5 Rights Upon Expiration.
EPIcyte shall have a royalty-free, exclusive license under the Scripps Patent Rights upon the expiration of this Agreement upon its regularly scheduled expiration date as recited in Section 2.6 and shall have no other obligations to Scripps
other than the obligation of EPIcyte to make any and all reports and payments for the final quarter period. Provided, however, that upon such expiration, each party shall be required to continue to abide by its non-disclosure obligations as
described in Section 7. 1, and EPIcyte shall continue to abide by its obligation to indemnify Scripps as described in Section 4.3 and by its obligations under Section 6.2 hereof. 
 8.6 Rights Upon Termination. Notwithstanding any other provision of this Agreement, upon any termination of this Agreement prior to the regularly
scheduled expiration date of this Agreement, the license granted hereunder shall terminate. Except as otherwise provided in Section 8.6 of this Agreement with respect to work-in-progress, upon such termination, EPIcyte shall have no further
right to develop, manufacture or market any Licensed Product, or to otherwise use any Scripps Patent Rights. Upon any such termination, EPIcyte shall promptly return all materials, samples, documents, information, and other materials which embody or
disclose Scripps Patent Rights; provided, however, that EPIcyte shall not be obligated to provide Scripps with proprietary information which EPIcyte can show that it independently developed. Any such termination shall not relieve either party from
any obligations accrued to the date of such termination. Upon such termination, each party shall be required to abide by its nondisclosure obligations as described in Section 7.1, and EPIcyte shall continue to abide by its obligations to
indemnify Scripps as described in Section 4.3. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 12 

 8.7 Work-in-Progress. Upon any such early termination of the license granted hereunder in
accordance with this Agreement, EPIcyte shall be entitled to finish any work-in-progress and to sell any completed inventory of a Licensed Product covered by such license which remain on hand as of the date of the termination, so long as EPIcyte
pays to Scripps the royalties applicable to said subsequent sales in accordance with the terms and conditions as set forth in this Agreement, provided that no such sales shall be permitted after the expiration of six (6) months after the date
of termination. 
 9. Assignment; Successors. 
 9.1 Assignment. Neither this Agreement nor any rights granted hereunder may be assigned or transferred by EPIcyte except (i) to an Affiliate of EPIcyte or (ii) to an entity acquiring all or
substantially all of its assets or acquiring, through purchase, merger or otherwise, more than fifty percent (50%) of the voting power of EPIcyte’s outstanding securities or (iii) as expressly permitted hereunder, without the prior
written consent of Scripps. 
 9.2 Binding Upon Successors and Assigns. Subject to the limitations on assignment herein, this
Agreement shall be binding upon and inure to the benefit of any successors in interest and assigns of Scripps and EPIcyte. Any such successor or assignee of EPIcyte’s interest shall expressly assume in writing the performance of all the terms
and conditions of this Agreement to be performed by EPIcyte. 
 10. General Provisions. 
 10.1 Independent Contractors. The relationship between Scripps and EPIcyte is that of independent contractors. Scripps and EPIcyte are not joint
venturers, partners, principal and agent, master and servant, employer or employee, and have no other relationship other than independent contracting parties. Scripps and EPIcyte shall have no power to bind or obligate each other in any manner,
other than as is expressly set forth in this Agreement. 
 10.2 Arbitration. Any controversy or claim arising out of or relating to
this Agreement, or the breach thereof, shall be settled by binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”), and the procedures set forth below. In the event of any
inconsistency between the Rules of AAA and the procedures set forth below, the procedures set forth below shall control. Judgment upon the award rendered by the arbitrators may be enforced in any court having jurisdiction thereof. 
 10.2.1 Location. The location of the arbitration shall be in the County of San Diego. 
 10.2.2 Selection of Arbitrators. The arbitration shall be conducted by a panel of three neutral arbitrators who are independent and disinterested
with respect to the parties, this Agreement, and the outcome of the arbitration. Each party shall appoint one neutral arbitrator, and these two arbitrators so selected by the parties shall then select the third arbitrator. If one party has given
written notice to the other party as to the identity of the arbitrator appointed by the party, and the party thereafter makes a written demand on the other party to appoint its designated arbitrator within the next ten days, and the other party
fails to appoint its designated arbitrator within ten days after receiving said written demand, then the arbitrator who has already been designated shall appoint the other two arbitrators. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 13 

 10.2.3 Discovery. Unless the parties mutually agree in writing to some additional and specific
pre-hearing discovery, the only pre-hearing discovery shall be (a) reasonably limited production of relevant and non-privileged documents, and (b) the identification of witnesses to be called at the hearing, which identification shall give
the witness’s name, general qualifications and position, and a brief statement as to the general scope of the testimony to be given by the witness. The arbitrators shall decide any disputes and shall control the process concerning these
pre-hearing discovery matters. Pursuant to the Rules of AAA, the parties may subpoena witnesses and documents for presentation at the hearing. 
 10.2.4 Case Management. Prompt resolution of any dispute is important to both parties; and the parties agree that the arbitration of any dispute shall be conducted expeditiously. The arbitrators are instructed and directed to assume
case management initiative and control over the arbitration process (including scheduling of events, pre-hearing discovery and activities, and the conduct of the hearing), in order to complete the arbitration as expeditiously as is reasonably
practical for obtaining a just resolution of the dispute. 
 10.2.5 Remedies. The arbitrators may grant any legal or equitable remedy
or relief that the arbitrators deem just and equitable, to the same extent that remedies or relief could be granted by a state or federal court, provided however, that no punitive damages may be awarded. No court action may be maintained seeking
punitive damages. The decision of any two of the three arbitrators appointed shall be binding upon the parties. 
 10.2.6 Expenses.
The expenses of the arbitration, including the arbitrators’ fees, expert witness fees, and attorney’s fees, may be awarded to the prevailing party, in the discretion of the arbitrators, or may be apportioned between the parties in any
manner deemed appropriate by the arbitrators. Unless and until the arbitrators decide that one party is to pay for all (or a share) of such expenses, both parties shall share equally in the payment of the arbitrators’ fees as and when billed by
the arbitrators. 
 10.2.7 Confidentiality. Except as set forth below, the parties shall keep confidential the fact of the
arbitration, the dispute being arbitrated, and the decision of the arbitrators. Notwithstanding the foregoing, the parties may disclose information about the arbitration to persons who have a need to know, such as directors, trustees, management
employees, witnesses, experts, investors, attorneys, lenders, insurers, and others who may be directly affected. Additionally, if a party has stock which is publicly traded, the party may make such disclosures as are required by applicable
securities laws. Further, if a party is expressly asked by a third party about the dispute or the arbitration, the party may disclose and acknowledge in general and limited terns that there is a dispute with the other party which is being (or has
been) arbitrated. Once the arbitration award has become final, if the arbitration award is not promptly satisfied, then these confidentiality provisions shall no longer be applicable. 
 10.3 Entire Agreement; Modification. This Agreement sets forth the entire agreement and understanding between the parties as to the subject matter
hereof. There shall be no amendments or modifications to this Agreement, except by a written document which is signed by both parties. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 14 

 10.4 California Law. This Agreement shall be construed and enforced in accordance with the laws of
the State of California. 
 10.5 Headings. The headings for each article and section in this Agreement have been inserted for
convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 
 10.6 Severability. Should any one or more of the provisions of this Agreement be held invalid or unenforceable by a court of competent jurisdiction, it shall be considered severed from this Agreement and shall
not serve to invalidate the remaining provisions thereof. The parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by them when entering this
Agreement may be realized. 
 10.7 No Waiver. Any delay in enforcing a party’s rights under this Agreement or any waiver as to a
particular default or other matter shall not constitute a waiver of such party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a
particular period of time. 
 10.8 Name. Whenever there has been an assignment or a sublicense by EPIcyte as permitted by this
Agreement, the term “EPIcyte” as used in this Agreement shall also include and refer to, if appropriate, such assignee or sublicensee. 
 10.9 Attorneys’ Fees. In the event of a dispute between the parties hereto or in the event of any default hereunder, the party prevailing in the resolution of any such dispute or default shall be entitled to recover its
reasonable attorneys’ fees and other costs incurred in connection with resolving such dispute or default. 
 10.10 Notices. Any
notices required by this Agreement shall be in writing, shall specifically refer to this Agreement and shall be sent by registered or certified airmail, postage prepaid, or by telefax, telex or cable, charges prepaid, or by overnight courier,
postage prepaid and shall be forwarded to the respective addresses set forth below unless subsequently changed by written notice to the other party: 
  

			
	For Scripps	  	The Scripps Research Institute
		  	10550 North Torrey Pines Road, TPC-9
		  	La Jolla, California 92037
		  	Attention: Director, Technology Development
		  	Fax No.: (619) 784-9910
		
	For EPIcyte:	  	EPIcyte Pharmaceutical, Inc.
		  	8445 Camino Santa Fe, Suite 102
		  	San Diego, California 92121
		  	Attention: President
		  	Fax No.: 619-554-0288

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 15 

 Notice shall be deemed delivered upon the earlier of (i) when received, (ii) three (3) days after deposit
into the mail, or (iii) the date notice is sent via telefax, telex or cable, (iv) the day immediately following delivery to overnight courier (except Sunday and holidays). 
 10.11 Compliance with U.S. Laws. Nothing contained in this Agreement shall require or permit Scripps or EPIcyte to do any act inconsistent with
the requirements of any United States law, regulation or executive order as the same may be in effect from time to time. 
 IN WITNESS
WHEREOF, the parties have executed this Agreement by their duly authorized representatives as of the date set forth above. 
  

									
	SCRIPPS:	 		 		 	EPIcyte:	 	
			
	THE SCRIPPS RESEARCH INSTITUTE	 		 	EPICYTE PHARMACEUTICAL, INC.
					
	By:	 	 /s/ Illegible
	 		 	By:	 	 /s/ Illegible

					
	Title:	 	 Senior Vice President
	 		 	Title:	 	 President

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 16 

 EXHIBIT A 
 PATENT ESTATE: 184 SERIES 
  

			
	10/09/97	 	Page 1

  

													
	 TSRI
 Ref Number
	  	 OPC
 Ref Number
	  	 Serial Number
 Filing Date
	  	 Patent Number
 Issue Date
	  	 Inventors
	  	 Title
	  	 Status

	0184.1	  	TSR 0155P	  	 07/591.823
  
 10/02/90
	  	 5,202.422
  
 4/13/93
	  	HIATT. HEIN	  	COMPOSITIONS CONTAINING PLANT-PRODUCED GLYCOPOLYPEPTIDE MULTIMERS, MULTIMERIC PROTEINS AND METHODS OF THEIR USE (DISCL. NOS. 89-14, ADDENDUM. 90-42) [CPA]	  	ISSUED
							
	0184.1 CON 1	  	TSR 0156P	  	 07/971.951
  
 11/05/92
	  	 5,639.947
  
 6/17/97
	  	HIATT. HEIN	  	COMPOSITIONS CONTAINING GLYCOPOLYPEPTIDE MULTIMERS AND THEIR USE (DISCL. NO. 89-14)	  	ISSUED
							
	0184.1 EP	  	TSR 0157P	  	 90917366.8
  
 10/25/90
	  		  	HIATT. HEIN	  	COMPOSITIONS CONTAINING PLANT-PRODUCED GLYCOPEPTIDE MULTIMERS, MULTIMERIC PROTEINS AND THEIR USE (EPO) [CPA]	  	PENDING
							
	0184.1 JP	  	TSR 0175P	  	 3-500436
  
 10/25/90
	  		  	HIATT. HEIN	  	COMPOSITIONS CONTAINING PLANT-PRODUCED GLYCOPEPTIDE MULTIMERS, MULTIMERIC PROTEINS AND THEIR USE (JAPAN)	  	PENDING
							
	0184.1 PC	  	TSR 0158P	  	 90/06179
  
 10/25/90
	  	 WO 91/06320
  
 6/16/91
	  	HIATT. HEIN	  	COMPOSITIONS CONTAINING PLANT-PRODUCED GLYCOPEPTIDE MULTIMERS, MULTIMERIC PROTEINS AND THEIR USE (PCT)	  	PUBLISHED
							
	0184.2	  	TSR 0181P	  	 08/642.406
  
 5/03/96
	  		  	HEIN. HIATT. MA	  	TRANSGENIC PLANTS EXPRESSING ASSEMBLED SECRETORY ANTIBODIES (DISCL. NO. 96-68)	  	PENDING
							
	0184.2 PC	  	TSR 0218P	  	 97/07562
  
 5/05/97
	  		  	HEIN. HIATT. MA	  	TRANSGENIC PLANTS EXPRESSING ASSEMBLED SECRETORY ANTIBODIES (PCT)	  	PENDING

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 17 

 EXHIBIT C 
 Obligations Related to Commercialization: 
 As described in Sections 2.2 and 4.1, EPIcyte and Scripps agree to certain
obligations related to commercial development of the Plantibodies Technology Patents by EPIcyte. 
 C.1.1 Milestones for Commercial Development in the
Medical Field - During the first three years of this agreement EPIcyte will demonstrate performance toward its commercial obligations by expenditures of greater than Two Million Dollars ($2,000,000) for combined research, development and
commercialization efforts of products in the Medical Field. These monies will be expended by EPIcyte, its collaborators, partners, and subcontractors. At the end of the third year, EPIcyte will have a minimum of five (5) full time equivalent
personnel employed by EPIcyte, its agent, contractor, and subcontractors and dedicated to research, development and commercialization efforts of products in the Medical Field under Scripps Patent Rights. During this time frame, EPIcyte will make
reasonable effort to sublicense the Plantibodies Technology Patents in the Medical Field where EPIcyte does not intend to develop its own products, to partner with other entities for production and distribution of products under the Plantibodies
Technology Patents and to develop its own products. 
 C.1.2 Milestones for Commercial Development in All Fields other than the Medical Field - In All
Fields other than the Medical Field over the first three (3) years EPIcyte, its agent, contractor, and subcontractors will demonstrate performance toward its commercial obligations by expenditures exceeding One Million Dollars ($1,000,000) for
combined research, development and commercialization efforts of products in All Fields other than the Medical Field. At the end of the third year, EPIcyte will have a minimum of three (3) full time equivalent personnel employed by EPIcyte, its
agent, contractor, and subcontractors and dedicated to research, development and commercialization efforts of products in All Fields other than the Medical Field under Scripps Patent Rights. During this time frame, EPIcyte will make every reasonable
effort to sublicense the Plantibodies Technology Patents in All Fields other than the Medical Field where EPIcyte does not intend to develop its own products, to partner with other entities for production and distribution of products under the
Plantibodies Technology Patents and to develop its own products. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]